ALK-Rearranged Non-Small Cell Lung Cancer

MONDO:0005233 Pathograph 18 Show in embeddings browser non-small cell lung carcinoma

ALK-rearranged non-small cell lung cancer (NSCLC) is a molecular subtype defined by a somatic ALK fusion oncoprotein, most commonly EML4::ALK from a chromosome 2 inversion. It accounts for a cohort-dependent minority of NSCLC and is enriched among younger people and never-smokers, but those demographic associations are neither causal mechanisms nor diagnostic criteria. Adenocarcinoma is the predominant histology, with rare ALK-rearranged squamous cancers reported. ALK tyrosine kinase inhibitors produce substantial systemic and intracranial disease control; CNS progression and acquired on-target or bypass resistance remain important disease-management challenges.

Ask OpenScientist

Ask a research question about ALK-Rearranged Non-Small Cell Lung Cancer. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

8
Pathophys.
1
Histopath.
2
Phenotypes
2
Hypotheses
18
Pathograph
2
Genes
7
Medical Actions
2
Subtypes
7
Trials
40
References
3
Deep Research
🏷

Classifications

ICD-O Morphology
Carcinoma
Harrison's Part
ONCOLOGY HEMATOLOGY
◆

Subtypes

2
EML4::ALK fusion-positive NSCLC
EML4 is the dominant ALK fusion partner in NSCLC. Different EML4 breakpoints create molecular variants; variant 3 may be associated with poorer outcomes in pooled studies, but it is not an established treatment-selection marker and ALEX did not find variant-specific alectinib efficacy differences.
Show evidence (3 references)
PMID:17625570 SUPPORT Human Clinical
"Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells."
The discovery study identifies the defining EML4::ALK inversion and also reports transforming activity in cell and mouse models.
PMID:41959926 SUPPORT Human Clinical
"V3 was associated with shorter progression-free survival (PFS)"
The pooled association supports possible adverse prognostic value but does not establish a variant-directed treatment rule.
PMID:30902613 SUPPORT Human Clinical
"variants 1, 2, and 3/ab did not affect PFS, objective response rate, or duration of response."
ALEX bounds the meta-analytic signal by showing no efficacy difference across common variants in that alectinib trial.
Other ALK fusion-partner NSCLC
Less common ALK fusions use partners other than EML4. Published examples include KIF5B::ALK, TFG::ALK, and TNIP2::ALK; evidence for response and prognosis is partner-specific and much sparser than for EML4::ALK.
Show evidence (1 reference)
PMID:31521978 SUPPORT Human Clinical
"ALK rearrangements have been previously identified in about 5.1% of lung adenocarcinoma, including EML4-ALK fusion variants, KIF5B-ALK and TFG-ALK."
The report directly names non-EML4 partners but does not establish uniform behavior across all rare fusions.
◈

Mechanistic Hypotheses

2
Canonical ALK Fusion Mitogenic Signaling Model
canonical_alk_fusion_mitogenic_signaling_model CANONICAL
Evidence balance 2 support
A somatic ALK fusion creates a constitutively active kinase that assembles cytoplasmic signaling foci and sustains MAPK and PI3K-AKT output. The resulting ALK-dependent proliferation and survival program drives the predominantly adenocarcinoma NSCLC phenotype and creates a targetable oncogene dependence. Metastatic progression to the CNS uses additional general invasion, dissemination, and colonization steps rather than a demonstrated direct ALK-to-brain route.
Pathograph links
ALK fusion oncoprotein formation -> Constitutive ALK mitogenic and survival signaling DIRECT Fusion-mediated ALK activation produces ligand-independent kinase output and constitutive downstream signaling.
Constitutive ALK mitogenic and survival signaling -> ALK-dependent tumor-cell proliferation and survival INDIRECT KNOWN INTERMEDIATES Persistent ALK output maintains growth and survival through the PI3K-AKT and MEK-ERK pathways. Intermediates: PI3K-AKT survival signaling; MEK-ERK proliferative signaling
ALK-dependent tumor-cell proliferation and survival -> Lung Adenocarcinoma INDIRECT KNOWN INTERMEDIATES Sustained ALK-dependent proliferation and survival support malignant transformation into the predominantly adenocarcinoma NSCLC phenotype. Intermediates: clonal expansion; malignant transformation
ALK-dependent tumor-cell proliferation and survival -> Brain Metastases INDIRECT KNOWN INTERMEDIATES ALK-positive lung tumors can progress through the general metastatic cascade to clinically frequent brain metastases; an ALK-specific direct route to the brain is not asserted. Intermediates: local tumor progression and invasion; hematogenous dissemination; central nervous system colonization
Show evidence (2 references)
PMID:17625570 SUPPORT Model Organism
"Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and subcutaneous tumours in nude mice."
The discovery study demonstrates transforming activity of EML4::ALK in both cell culture and a mouse tumor model.
PMID:20952506 SUPPORT Model Organism
"To evaluate potential treatment strategies for lung cancers driven by an activated EML4-ALK chimeric oncogene, we generated a genetically engineered mouse model that phenocopies the human disease where this rearranged gene arises."
The inducible mouse model supports an ALK-fusion-driven lung-tumor program while remaining preclinical evidence.
Acquired ALK TKI Resistance Model
acquired_alk_tki_resistance_model CANONICAL
Evidence balance 2 support
Exposure to ALK-directed therapy imposes selection pressure that can produce on-target ALK kinase-domain mutations or preserve tumor-cell survival through adaptive kinase signaling, microenvironmental bypass, and phenotypic state changes such as EMT. The existence of these resistance classes is established; many specific combination strategies remain preclinical, and no single later-generation ALK inhibitor suppresses every bypass or compound resistance state.
Pathograph links
ALK TKI therapeutic selection pressure -> ALK kinase-domain mutation-mediated resistance INDIRECT KNOWN INTERMEDIATES ALK-TKI pressure can select kinase-domain substitutions that reduce inhibitor binding or alter drug-specific sensitivity. Intermediates: survival of mutation-bearing tumor subclones; expansion during ALK inhibition
ALK TKI therapeutic selection pressure -> Adaptive kinase-bypass resistance INDIRECT KNOWN INTERMEDIATES Resistant cells can restore growth signaling through alternate kinase pathways despite continued ALK inhibition. Intermediates: compensatory receptor tyrosine kinase activation; restoration of downstream survival signaling
ALK TKI therapeutic selection pressure -> Microenvironment-mediated ALK bypass resistance INDIRECT KNOWN INTERMEDIATES Fibroblast- and macrophage-derived signals can preserve resistant tumor cell survival through MET, integrin, or GAS6-AXL pathways. Intermediates: stromal growth-factor or matrix signaling; MET-integrin or GAS6-AXL survival output
ALK TKI therapeutic selection pressure -> EMT-associated ALK TKI resistance INDIRECT KNOWN INTERMEDIATES In a G1202R cell model, STAT3-Slug signaling accompanies an invasive EMT state and reduced ceritinib sensitivity. Intermediates: STAT3-Slug activation; epithelial-to-mesenchymal state transition
Show evidence (2 references)
PMID:37149843 SUPPORT Other
"However, resistance to ALK inhibitors can occur via point-mutations within the kinase domain of the EML4-ALK fusion, for example G1202R, reducing inhibitor effectiveness."
This review supports the established on-target mutation class while not implying that all resistance is ALK-dependent.
PMID:28676215 SUPPORT Human Clinical
"We conclude that the T1151K ALK mutation confers resistance to ceritinib, which may be rescued by alectinib or lorlatinib as evidenced by this clinical narrative."
The patient narrative directly connects sequential ALK-TKI exposure with an acquired on-target resistance mutation and differential drug response.
⚙

Pathophysiology

8
ALK fusion oncoprotein formation
A somatic inversion or translocation preserves the ALK kinase domain and joins it to an N-terminal partner. EML4::ALK is the dominant exemplar in NSCLC; other partners can create the same disease-defining class without necessarily reproducing every EML4-specific assembly property.
Canonical ALK Fusion Mitogenic Signaling Model
ALK hgnc:427 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves ALK (hgnc:427). hgnc:427 is a gene from the HUGO Gene Nomenclature Committee. EML4 hgnc:1316 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves EML4 (hgnc:1316). hgnc:1316 is a gene from the HUGO Gene Nomenclature Committee.
protein tyrosine kinase activity GO:0004713 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves increased protein tyrosine kinase activity (GO:0004713). GO:0004713 is a molecular function from the Gene Ontology. ↑ INCREASED
Downstream
Constitutive ALK mitogenic and survival signaling Fusion-mediated ALK activation produces ligand-independent kinase output and constitutive downstream signaling. Canonical ALK Fusion Mitogenic Signaling Model
Show evidence (2 references)
PMID:17625570 SUPPORT Human Clinical
"Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells."
The discovery study directly identifies the chromosome 2 inversion and EML4::ALK fusion in NSCLC cells.
CIVIC_ASSERTION:3 SUPPORT Other
"ALK-FUSIONS are found in 3-5% of non-small cell lung cancer and act as a targetable driver mutation."
The accepted CIViC assertion independently classifies ALK fusions as targetable NSCLC driver alterations.
Constitutive ALK mitogenic and survival signaling
Active EML4::ALK assembles cytoplasmic signaling foci containing MAPK and PI3K pathway components. Sustained kinase output engages MEK-ERK and PI3K-AKT survival programs; JAK-STAT is not asserted here as a universal disease-level branch because the attached evidence is variant- and context-dependent.
Canonical ALK Fusion Mitogenic Signaling Model
Ras protein signal transduction GO:0007265 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Ras protein signal transduction (GO:0007265). GO:0007265 is a biological process from the Gene Ontology. ↑ INCREASED ERK1 and ERK2 cascade GO:0070371 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased ERK1 and ERK2 cascade (GO:0070371). GO:0070371 is a biological process from the Gene Ontology. ↑ INCREASED phosphatidylinositol 3-kinase signaling GO:0043491 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased phosphatidylinositol 3-kinase signaling, annotated with phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0043491). GO:0043491 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
ALK-dependent tumor-cell proliferation and survival Persistent ALK output maintains growth and survival through the PI3K-AKT and MEK-ERK pathways. Canonical ALK Fusion Mitogenic Signaling Model
Show evidence (1 reference)
PMID:34661367 SUPPORT In Vitro
"Here, we show that EML4-ALK V1 and V3 proteins form cytoplasmic foci that contain components of the MAPK, PLCγ and PI3K signalling pathways."
Cell experiments directly localize core signaling components to EML4::ALK assemblies.
ALK-dependent tumor-cell proliferation and survival
ALK-rearranged tumor cells depend on continued fusion-kinase signaling for proliferation and survival. This is a targetable oncogene dependence, not a claim that ALK expression alone transforms every human lung-cell context.
Canonical ALK Fusion Mitogenic Signaling Model
cell population proliferation GO:0008283 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell population proliferation (GO:0008283). GO:0008283 is a biological process from the Gene Ontology. ↑ INCREASED apoptotic process GO:0006915 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased apoptotic process (GO:0006915). GO:0006915 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Lung Adenocarcinoma Sustained ALK-dependent proliferation and survival support malignant transformation into the predominantly adenocarcinoma NSCLC phenotype. Canonical ALK Fusion Mitogenic Signaling Model
Brain Metastases ALK-positive lung tumors can progress through the general metastatic cascade to clinically frequent brain metastases; an ALK-specific direct route to the brain is not asserted. Canonical ALK Fusion Mitogenic Signaling Model
Show evidence (1 reference)
PMID:20952506 SUPPORT In Vitro
"These findings suggest that EML4-ALK–driven cancers display features of oncogene dependence or addiction and that ALK inhibitors may be particularly effective for this lung cancer subset."
The preclinical study explicitly frames the ALK-rearranged model as oncogene-dependent.
ALK TKI therapeutic selection pressure
ALK-directed therapy suppresses sensitive tumor cells while creating a treatment-conditioned selection environment in which resistant on-target clones, adaptive signaling programs, microenvironmental rescue, or altered cell states can persist and expand. Treatment exposure—not oncogene dependence by itself—is the proximal context for acquired resistance.
Acquired ALK TKI Resistance Model
response to xenobiotic stimulus GO:0009410 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal response to xenobiotic stimulus (GO:0009410). GO:0009410 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
ALK kinase-domain mutation-mediated resistance ALK-TKI pressure can select kinase-domain substitutions that reduce inhibitor binding or alter drug-specific sensitivity. Acquired ALK TKI Resistance Model
Adaptive kinase-bypass resistance Resistant cells can restore growth signaling through alternate kinase pathways despite continued ALK inhibition. Acquired ALK TKI Resistance Model
Microenvironment-mediated ALK bypass resistance Fibroblast- and macrophage-derived signals can preserve resistant tumor cell survival through MET, integrin, or GAS6-AXL pathways. Acquired ALK TKI Resistance Model
EMT-associated ALK TKI resistance In a G1202R cell model, STAT3-Slug signaling accompanies an invasive EMT state and reduced ceritinib sensitivity. Acquired ALK TKI Resistance Model
Show evidence (1 reference)
PMID:28676215 SUPPORT Human Clinical
"Here we report for the first time a novel ALK T1151K mutation in a patient with metastatic ALK-rearranged NSCLC who progressed on crizotinib and then ceritinib."
The clinical sequence directly establishes treatment exposure before the acquired mutation was detected.
ALK kinase-domain mutation-mediated resistance
Secondary ALK kinase-domain substitutions can change inhibitor binding or ATP competition. G1202R is a solvent-front resistance mutation, while T1151K illustrates drug-specific resistance that may retain sensitivity to another ALK inhibitor. This node does not assert that a single agent covers all compound mutations.
ALK hgnc:427 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves ALK (hgnc:427). hgnc:427 is a gene from the HUGO Gene Nomenclature Committee.
response to xenobiotic stimulus GO:0009410 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal response to xenobiotic stimulus (GO:0009410). GO:0009410 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Show evidence (2 references)
CIVIC_EID:441 SUPPORT Other
"The G1202R mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells."
The accepted CIViC evidence item provides a bounded cell-model assertion for G1202R-mediated crizotinib resistance.
PMID:28676215 SUPPORT Human Clinical
"We conclude that the T1151K ALK mutation confers resistance to ceritinib, which may be rescued by alectinib or lorlatinib as evidenced by this clinical narrative."
This patient report demonstrates drug-specific sensitivity rather than uniform class resistance.
Adaptive kinase-bypass resistance
Resistant tumor cells can restore survival output through alternate receptor or intracellular kinases, including EGFR and SRC. The attached perturbation evidence is preclinical, so proposed combination strategies are not represented as established care.
cell surface receptor protein tyrosine kinase signaling pathway GO:0007169 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell surface receptor protein tyrosine kinase signaling pathway (GO:0007169). GO:0007169 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (2 references)
PMID:24199682 SUPPORT In Vitro
"We identified activation of EGFR as a mechanism of resistance to crizotinib in preclinical models of ALK translocated NSCLC."
The authors explicitly bound the EGFR result to preclinical resistant models.
PMID:38521003 SUPPORT In Vitro
"Co-targeting of ALK and SRC showed remarkable inhibitory effects"
Cell-model co-targeting supports SRC as a candidate bypass dependency, not a clinically validated combination.
Microenvironment-mediated ALK bypass resistance
Cancer-associated fibroblasts and tumor-associated macrophages can supply paracrine or matrix-associated signals that maintain resistant-cell survival through MET-integrin or GAS6-AXL pathways.
cell surface receptor protein tyrosine kinase signaling pathway GO:0007169 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell surface receptor protein tyrosine kinase signaling pathway (GO:0007169). GO:0007169 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (2 references)
PMID:41433419 SUPPORT In Vitro
"Concurrent targeting of MET and integrin signaling effectively abrogated ALK inhibitor resistance in EML4-ALK+ NSCLC cells cocultured with CAFs."
The coculture perturbation directly supports a stromal MET-integrin rescue mechanism.
PMID:39904499 SUPPORT Model Organism
"These findings suggest that AXL expression in resistant cancer cells, combined with increased Gas6 production in the TME, contributes to enhanced ALK-TKI resistance."
The study combines tumor and microenvironment models to support a GAS6-AXL resistance axis.
EMT-associated ALK TKI resistance
In an EML4::ALK G1202R cell model, STAT3-Slug activation induces an epithelial-to-mesenchymal state with increased migration and invasion and reduced ceritinib sensitivity. Its prevalence and treatment implications in patients remain unresolved.
epithelial to mesenchymal transition GO:0001837 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased epithelial to mesenchymal transition (GO:0001837). GO:0001837 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (1 reference)
PMID:35085771 SUPPORT In Vitro
"In conclusion, these data indicate that the EML4-ALK G1202R mutation mediates the EMT phenotype by activating the STAT3/Slug signaling pathway, resulting in resistance to ceritinib"
The conclusion directly supports the bounded G1202R-STAT3-Slug cell-model branch.
✶

Histopathology

1
Adenocarcinoma-predominant morphology
ALK-rearranged NSCLC is enriched in adenocarcinoma and can show acinar, cribriform, or solid growth, mucin production, and signet-ring-cell elements. Rare molecularly confirmed ALK-rearranged squamous carcinomas prevent an exclusive-adenocarcinoma formulation.
Show evidence (3 references)
PMID:22129856 SUPPORT Human Clinical
"Similar to EGFR-mutated lung cancer, ALK-rearranged lung cancer was enriched in adenocarcinoma, women, and never-smokers."
This ALK-specific cohort supports adenocarcinoma enrichment without an unsupported universal frequency band.
PMID:26095438 SUPPORT Human Clinical
"Acinar, cribriform, and solid growth patterns, extracellular and intracellular mucin production, and presence of signet-ring-cell element, and psammoma body were significantly more often present in ALK-positive cancer."
Direct histologic comparison supports the morphology described for ALK-positive pulmonary adenocarcinoma.
PMID:40783309 SUPPORT Human Clinical
"DNA-based next-generation sequencing (NGS) has identified ALK rearrangements in lung squamous cell carcinoma (LUSC), a subset of nonsmall cell lung cancer traditionally lacking effective targeted therapies."
This recent cohort establishes the rare squamous exception but does not quantify its frequency among all ALK-positive cancers.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for ALK-Rearranged Non-Small Cell Lung Cancer Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

2
Neoplasm 1
Lung Adenocarcinoma HP:0030078 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Lung adenocarcinoma (HP:0030078). HP:0030078 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22129856 SUPPORT Human Clinical
"ALK rearrangement was significantly higher in adenocarcinomas (6.8%, p<0.001)"
The ALK-specific surgical cohort supports the predominant adenocarcinoma phenotype while not excluding other NSCLC histologies.
Other 1
Brain Metastases FREQUENT Brain neoplasm HP:0030692 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Brain metastasis, annotated with Brain neoplasm (HP:0030692). HP:0030692 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34147645 SUPPORT Other
"Brain metastases are quite frequent in patients with ALK-translocated non-small cell lung cancer (NSCLC)"
The review directly supports frequent brain metastasis as a clinical manifestation.
🧬

Genetic Associations

2
ALK (Somatic Rearrangement)
Gene: ALK hgnc:427 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ALK (hgnc:427). hgnc:427 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (2 references)
PMID:17625570 SUPPORT Human Clinical
"a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene"
The discovery study directly identifies the somatic chromosome 2 event joining EML4 and ALK in NSCLC cells.
CIVIC_ASSERTION:3 SUPPORT Other
"ALK-FUSIONS are found in 3-5% of non-small cell lung cancer and act as a targetable driver mutation."
CIViC's accepted assertion supports ALK fusions as defining, targetable genetic drivers in NSCLC.
EML4 (Fusion Partner)
Gene: EML4 hgnc:1316 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is EML4 (hgnc:1316). hgnc:1316 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (1 reference)
PMID:17625570 SUPPORT Human Clinical
"a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene"
The original report directly identifies EML4 as the fusion partner in the transforming EML4::ALK lesion.
🗃️

External Assertions

3
CIViC ALK fusion crizotinib sensitivity assertion
CIViC accepted assertion CIVIC_ASSERTION:3
CIViC accepted assertion that ALK fusion-positive non-small cell lung carcinoma predicts sensitivity/response to crizotinib.
01-May-2026 CIViC accepted assertion: molecular_profile="v::ALK Fusion"; disease="Lung Non-small Cell Carcinoma"; assertion_type=Predictive; significance=Sensitivity/Response; therapy=Crizotinib; AMP category=Tier I - Level A.
Show evidence (1 reference)
CIVIC_ASSERTION:3 SUPPORT Other
"Lung adenocarcinoma positive for ALK-FUSIONS have been found to be sensitive to crizotinib treatment"
CIViC records an accepted predictive sensitivity assertion for ALK fusion and crizotinib in NSCLC.
CIViC ALK fusion alectinib sensitivity assertion
CIViC accepted assertion CIVIC_ASSERTION:34
CIViC accepted assertion that ALK fusion-positive non-small cell lung carcinoma predicts sensitivity/response to alectinib.
01-May-2026 CIViC accepted assertion: molecular_profile="v::ALK Fusion"; disease="Lung Non-small Cell Carcinoma"; assertion_type=Predictive; significance=Sensitivity/Response; therapy=Alectinib; AMP category=Tier I - Level A.
Show evidence (1 reference)
CIVIC_ASSERTION:34 SUPPORT Other
"ALK fusion positive NSCLC is sensitive to alectinib"
CIViC records an accepted predictive sensitivity assertion for ALK fusion and alectinib in NSCLC.
CIViC EML4::ALK plus ALK G1202R crizotinib resistance evidence item
CIViC accepted evidence item CIVIC_EID:441
CIViC accepted evidence item linking EML4::ALK fusion with ALK G1202R in non-small cell lung cancer to crizotinib resistance.
01-May-2026 CIViC accepted evidence item: molecular_profile="EML4::ALK Fusion AND ALK G1202R"; evidence_type=Predictive; evidence_level=D; significance=Resistance; therapy=Crizotinib; citation_id=PMID:22277784.
Show evidence (1 reference)
CIVIC_EID:441 SUPPORT Other
"The G1202R mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells."
CIViC records an accepted predictive resistance evidence item for ALK G1202R and crizotinib in NSCLC.
💊

Medical Actions

7
Alectinib
Action: targeted therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is targeted therapy (NCIT:C93352). NCIT:C93352 is a clinical intervention from the NCI Thesaurus. Ontology label: Targeted Therapy NCIT:C93352
Agent: alectinib CHEBI:90936 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses alectinib (CHEBI:90936). CHEBI:90936 is a therapeutic agent from Chemical Entities of Biological Interest.
A second-generation ALK inhibitor used in advanced ALK-positive NSCLC and, in a distinct disease setting, as adjuvant therapy after complete resection. In ALEX it prolonged progression-free survival relative to crizotinib; in ALINA it improved disease-free survival relative to platinum chemotherapy for resected stage IB (tumors at least 4 cm), II, or IIIA disease. Overall survival data from ALINA were immature in the cited analysis.
Mechanism Target:
INHIBITS Constitutive ALK mitogenic and survival signaling — Alectinib (CH5424802) inhibits ALK kinase activity and suppresses growth driven by EML4::ALK.
Show evidence (1 reference)
PMID:21575866 SUPPORT In Vitro
"showing preferential antitumor activity against cancers with gene alterations of ALK, such as nonsmall cell lung cancer (NSCLC) cells expressing EML4-ALK fusion"
Preclinical data directly support inhibition of the ALK-dependent growth program represented by this target node.
🔬 3D Structures:
3AOX X-ray 1.75 Å ⚗️ alectinib
Wild-type ALK kinase domain in complex with CH5424802 (alectinib); this structure should not be interpreted as a mutant co-crystal.
Show evidence (3 references)
PMID:30902613 SUPPORT Human Clinical
"The median PFS times were 34.8 months with alectinib and 10.9 months with crizotinib."
The updated randomized ALEX analysis directly supports longer progression-free survival with first-line alectinib.
PMID:38598794 SUPPORT Human Clinical
"adjuvant alectinib significantly improved disease-free survival"
ALINA directly supports the separate adjuvant indication after complete resection of stage IB-IIIA ALK-positive NSCLC.
CIVIC_ASSERTION:34 SUPPORT Other
"ALK fusion positive NSCLC is sensitive to alectinib"
CIViC's accepted assertion directly supports alectinib sensitivity in ALK fusion-positive NSCLC.
Lorlatinib
Action: targeted therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is targeted therapy (NCIT:C93352). NCIT:C93352 is a clinical intervention from the NCI Thesaurus. Ontology label: Targeted Therapy NCIT:C93352
Agent: lorlatinib CHEBI:143117 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses lorlatinib (CHEBI:143117). CHEBI:143117 is a therapeutic agent from Chemical Entities of Biological Interest.
A third-generation, brain-penetrant ALK inhibitor used for advanced ALK-positive NSCLC. Seven-year CROWN follow-up showed durable systemic and intracranial control relative to crizotinib. Preclinical data support activity across wild-type ALK and multiple single kinase-domain resistance mutations; this does not imply control of bypass signaling or every compound mutation.
Mechanism Target:
INHIBITS Constitutive ALK mitogenic and survival signaling — Lorlatinib inhibits the ALK kinase program maintained by the fusion oncoprotein.
Show evidence (1 reference)
PMID:24819116 SUPPORT In Vitro
"These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clinically reported ALK kinase domain mutations."
The lorlatinib discovery study directly supports inhibition of wild-type fusion-driven ALK signaling.
INHIBITS ALK kinase-domain mutation-mediated resistance — Lorlatinib retains preclinical potency against multiple clinically reported single ALK kinase-domain mutations.
Show evidence (1 reference)
PMID:24819116 SUPPORT In Vitro
"These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clinically reported ALK kinase domain mutations."
The preclinical evidence supports an on-target resistance link while not extending the claim to bypass or all compound resistance states.
🔬 3D Structures:
4CLI X-ray 2.05 Å ⚗️ lorlatinib
Wild-type ALK kinase domain in complex with PF-06463922 (lorlatinib); the entry is not a G1202R mutant co-crystal.
Show evidence (1 reference)
PMID:42217582 SUPPORT Human Clinical
"7-year PFS was 55% and 3%, respectively."
The mature CROWN update directly supports durable first-line benefit over crizotinib; overall-survival follow-up remained ongoing.
Ceritinib
Action: targeted therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is targeted therapy (NCIT:C93352). NCIT:C93352 is a clinical intervention from the NCI Thesaurus. Ontology label: Targeted Therapy NCIT:C93352
Agent: ceritinib CHEBI:78432 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses ceritinib (CHEBI:78432). CHEBI:78432 is a therapeutic agent from Chemical Entities of Biological Interest.
A second-generation ALK inhibitor with randomized first-line evidence in advanced ALK-rearranged nonsquamous NSCLC. ASCEND-4 showed longer progression-free survival than platinum/pemetrexed chemotherapy.
Mechanism Target:
INHIBITS Constitutive ALK mitogenic and survival signaling — Clinical selection by ALK rearrangement and randomized benefit support inhibition of the fusion-driven ALK signaling program.
Show evidence (1 reference)
PMID:28126333 SUPPORT Human Clinical
"First-line ceritinib showed a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy in patients with advanced ALK-rearranged NSCLC."
The biomarker-selected randomized trial supports therapeutic inhibition of the ALK-dependent disease mechanism.
Show evidence (1 reference)
PMID:28126333 SUPPORT Human Clinical
"Median progression-free survival (as assessed by blinded independent review committee) was 16·6 months (95% CI 12·6-27·2) in the ceritinib group and 8·1 months (5·8-11·1) in the chemotherapy group"
ASCEND-4 directly quantifies the progression-free-survival advantage of first-line ceritinib over chemotherapy.
Ensartinib
Action: targeted therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is targeted therapy (NCIT:C93352). NCIT:C93352 is a clinical intervention from the NCI Thesaurus. Ontology label: Targeted Therapy NCIT:C93352
Agent: ensartinib hydrochloride NCIT:C171676 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses ensartinib hydrochloride (NCIT:C171676). NCIT:C171676 is a therapeutic agent from the NCI Thesaurus.
An oral ALK inhibitor evaluated as first-line therapy for advanced ALK-positive NSCLC. In the phase III eXALT3 trial, ensartinib prolonged progression-free survival and improved intracranial response relative to crizotinib.
Mechanism Target:
INHIBITS Constitutive ALK mitogenic and survival signaling — Ensartinib is an ALK tyrosine-kinase inhibitor tested in molecularly selected ALK-positive tumors.
Show evidence (1 reference)
PMID:34473194 SUPPORT Human Clinical
"Ensartinib, an oral tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system efficacy for patients with ALK-positive non-small cell lung cancer (NSCLC)."
The randomized study directly identifies ensartinib as an ALK inhibitor and supports its link to the fusion-driven signaling target.
Show evidence (1 reference)
PMID:34473194 SUPPORT Human Clinical
"In this randomized clinical trial, ensartinib showed superior efficacy to crizotinib in both systemic and intracranial disease."
eXALT3 directly supports improved first-line progression-free survival with ensartinib relative to crizotinib.
Brigatinib
Action: targeted therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is targeted therapy (NCIT:C93352). NCIT:C93352 is a clinical intervention from the NCI Thesaurus. Ontology label: Targeted Therapy NCIT:C93352
Agent: brigatinib CHEBI:232810 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses brigatinib (CHEBI:232810). CHEBI:232810 is a therapeutic agent from Chemical Entities of Biological Interest.
A second-generation ALK inhibitor with randomized first-line evidence in advanced ALK-positive NSCLC. Final ALTA-1L results showed longer progression-free survival than crizotinib; overall survival was not reached in either group in that analysis.
Mechanism Target:
INHIBITS Constitutive ALK mitogenic and survival signaling — Clinical selection by ALK positivity and randomized benefit support inhibition of the fusion-driven ALK signaling program.
Show evidence (1 reference)
PMID:34537440 SUPPORT Human Clinical
"Brigatinib exhibited superior efficacy compared with crizotinib regardless of EML4-ALK variant and TP53 mutation."
The biomarker-selected trial supports brigatinib acting against the ALK-dependent disease program without claiming universal mutation coverage.
Show evidence (1 reference)
PMID:34537440 SUPPORT Human Clinical
"In the ALTA-1L final analysis, with longer follow-up, brigatinib continued to exhibit superior efficacy and tolerability versus crizotinib in patients with or without poor prognostic biomarkers."
Final ALTA-1L results directly support improved progression-free survival with brigatinib relative to crizotinib.
Crizotinib
Action: targeted therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is targeted therapy (NCIT:C93352). NCIT:C93352 is a clinical intervention from the NCI Thesaurus. Ontology label: Targeted Therapy NCIT:C93352
Agent: crizotinib CHEBI:64310 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses crizotinib (CHEBI:64310). CHEBI:64310 is a therapeutic agent from Chemical Entities of Biological Interest.
The first ALK inhibitor to establish randomized clinical benefit in advanced ALK-positive NSCLC. PROFILE 1014 showed longer progression-free survival than platinum/pemetrexed chemotherapy. It remains historically foundational while later-generation inhibitors provide other options.
Mechanism Target:
INHIBITS Constitutive ALK mitogenic and survival signaling — Crizotinib occupies the ATP-binding cleft of the ALK kinase domain, inhibiting the constitutive oncogenic signaling driven by ALK fusions.
Show evidence (1 reference)
PMID:21812414 SUPPORT In Vitro
"the clinical candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition"
The drug-discovery study directly supports ALK inhibition by crizotinib.
🔬 3D Structures:
2XP2 X-ray 1.9 Å ⚗️ crizotinib
Wild-type human ALK kinase domain in complex with crizotinib; this entry is distinct from the c-MET structure used earlier in structure-guided development.
Show evidence (2 references)
PMID:25470694 SUPPORT Human Clinical
"Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC."
PROFILE 1014 directly supports first-line crizotinib efficacy in advanced ALK-positive NSCLC.
CIVIC_ASSERTION:3 SUPPORT Other
"Lung adenocarcinoma positive for ALK-FUSIONS have been found to be sensitive to crizotinib treatment"
CIViC's accepted assertion directly supports crizotinib sensitivity in ALK fusion-positive NSCLC.
Platinum/pemetrexed chemotherapy
Action: ChemotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Chemotherapy (NCIT:C15632). NCIT:C15632 is a clinical intervention from the NCI Thesaurus. NCIT:C15632
Platinum plus pemetrexed is a studied cytotoxic regimen in advanced ALK-positive NSCLC. Its placement in an individual treatment sequence depends on stage, prior therapy, comorbidity, and current guidance and is not inferred from the retrospective cohort cited here.
Show evidence (1 reference)
PMID:22887466 SUPPORT Human Clinical
"Among 70 ALK-positive patients treated with a platinum/pemetrexed regimen, the median PFS (mPFS) was 7.3 months"
Directly supports platinum/pemetrexed chemotherapy as a studied regimen in advanced ALK-positive NSCLC.
🔬

Diagnosis

1
Tumor ALK fusion testing (REQUIRED_FOR_SUBTYPE_ASSIGNMENT)
Classification as ALK-rearranged NSCLC requires demonstration of ALK positivity in tumor material. Immunohistochemistry, break-apart FISH, and DNA- or RNA-based next-generation sequencing provide complementary protein, rearrangement, and expressed-fusion readouts. Discordant or complex results may require orthogonal confirmation; demographic enrichment is not an adequate substitute for testing.
Markers: ALK rearrangement; expressed ALK fusion; ALK protein expression
Results: Detection of an oncogenic ALK rearrangement, fusion transcript, or fusion-protein expression
Show evidence (3 references)
PMID:35624360 SUPPORT Human Clinical
"The concordance rates were 97.1% (34/35) for RNA-NGS, 94.7% (36/38) for IHC, and 97.4% (37/38) for FISH."
Direct method comparison supports the complementary use and high, but not perfect, concordance of molecular and protein assays.
PMID:37190044 SUPPORT Human Clinical
"targeted RNA NGS was confirmed to be the most efficient technique for gene fusion identification in clinical practice"
The prospective multicenter comparison supports RNA-based fusion identification in routine practice.
PMID:39016057 SUPPORT Human Clinical
"IHC-VENTANA-D5F3 was used in 53.6%, real-time polymerase chain reaction (RT-PCR) in 25.4%, next-generation sequencing (NGS) in 18.3%, and fluorescence in-situ hybridization (FISH) in 15.9% in the adenocarcinoma subgroup."
The real-world cohort demonstrates multimodal ALK testing rather than a single universally sufficient assay workflow.
🌍

Epidemiology

2
Cohort-dependent ALK-rearrangement frequency
ALK rearrangements define a minority molecular subtype whose measured frequency varies with histology, stage, population, and testing strategy. A surgical NSCLC cohort found 3.8%, whereas a large Chinese advanced-NSCLC cohort found 6.7%; these selected-cohort proportions are not population point-prevalence estimates.
Show evidence (2 references)
PMID:22129856 SUPPORT Human Clinical
"Of the 735 NSCLC cases, 28 (3.8%) were ALK FISH-positive."
This surgical cohort provides a directly measured ALK-positive fraction while defining the population and assay used.
PMID:39016057 SUPPORT Human Clinical
"The overall ALK gene rearrangement rate was 6.7% in 23,689 patients with advanced NSCLC and 8.2% in 17,436 patients with advanced lung adenocarcinoma."
This large advanced-disease cohort demonstrates that molecular-subtype fractions depend on the clinical and histologic denominator.
Younger-age and never-smoker enrichment
ALK-positive NSCLC is enriched among younger patients and never-smokers. These are epidemiologic associations, not downstream effects of ALK fusion signaling and not substitutes for tumor molecular testing.
Show evidence (2 references)
PMID:22129856 SUPPORT Human Clinical
"ALK rearrangement was significantly higher in adenocarcinomas (6.8%, p<0.001), younger age (p<0.0007), women (7.6%, p<0.001), and never-smokers (8.9%, p<0.001) with no gender difference in the adenocarcinoma or never-smoker subgroup."
The cohort directly supports age and smoking-status enrichment without implying a causal molecular pathway.
PMID:39016057 SUPPORT Human Clinical
"The overall ALK gene rearrangement rates were higher in females, patients of ≤ 35 years old, never smokers, tumor cellularity of > 50, and metastatic specimens used for testing in the total NSCLC population and adenocarcinoma subgroup (all P < 0.05)."
The nationwide cohort independently supports the demographic enrichment.
🔬

Clinical Trials

7
NCT02075840 PHASE_III COMPLETED
ALEX phase III trial comparing first-line alectinib with crizotinib in advanced ALK-positive NSCLC.
Show evidence (1 reference)
clinicaltrials:NCT02075840 SUPPORT Human Clinical
"This randomized, active controlled, multicenter phase III open-label study is designed to evaluate the efficacy and safety of alectinib compared with crizotinib treatment in participants with treatment-naive anaplastic lymphoma kinase-positive (ALK-positive) advanced non-small cell lung cancer (NSCLC)."
The cached registry summary supports the ALEX design and population; completion status was independently verified against the live registry on 2026-07-18.
NCT03052608 PHASE_III ACTIVE_NOT_RECRUITING
CROWN phase III trial comparing first-line lorlatinib with crizotinib in advanced ALK-positive NSCLC.
Show evidence (1 reference)
clinicaltrials:NCT03052608 SUPPORT Human Clinical
"A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survival in the same..."
The cached registry summary supports the CROWN design and endpoints; active-not-recruiting status was independently verified on 2026-07-18.
NCT03456076 PHASE_III ACTIVE_NOT_RECRUITING
ALINA phase III trial comparing adjuvant alectinib with platinum-based chemotherapy after complete resection.
Show evidence (1 reference)
clinicaltrials:NCT03456076 SUPPORT Human Clinical
"This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting."
The cached registry summary supports the ALINA adjuvant comparison; active-not-recruiting status was independently verified on 2026-07-18.
NCT01828099 PHASE_III COMPLETED
ASCEND-4 phase III trial comparing first-line ceritinib with platinum-pemetrexed chemotherapy.
Show evidence (1 reference)
clinicaltrials:NCT01828099 SUPPORT Human Clinical
"To compare the efficacy and safety of ceritinib with standard first-line chemotherapy (pemetrexed plus cisplatin or carboplatin) in patients with stage IIIB (not candidates for definitive multimodality therapy) or stage IV, non-squamous non-small cell lung cancer (NSCLC) harboring a confirmed..."
The cached registry summary supports the ASCEND-4 design and population; completion status was independently verified on 2026-07-18.
NCT02737501 PHASE_III COMPLETED
ALTA-1L phase III trial comparing first-line brigatinib with crizotinib in advanced ALK-positive NSCLC.
Show evidence (1 reference)
clinicaltrials:NCT02737501 SUPPORT Human Clinical
"The purpose of the study is to compare the efficacy of brigatinib to that of crizotinib in ALK+ locally advanced or metastatic non-small cell lung cancer (NSCLC) participants naive to ALK inhibitors, as evidenced by progression-free survival (PFS)."
The cached registry summary supports the ALTA-1L comparison and endpoint; completion status was independently verified on 2026-07-18.
NCT01154140 PHASE_III COMPLETED
PROFILE 1014 phase III trial comparing first-line crizotinib with platinum-pemetrexed chemotherapy.
Show evidence (1 reference)
clinicaltrials:NCT01154140 SUPPORT Human Clinical
"This study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with ALK positive lung cancer."
The cached registry summary supports the PROFILE 1014 comparison; completion status was independently verified on 2026-07-18.
NCT02767804 PHASE_III ACTIVE_NOT_RECRUITING
eXALT3 phase III trial comparing ensartinib with crizotinib in ALK-positive NSCLC.
Show evidence (1 reference)
clinicaltrials:NCT02767804 SUPPORT Human Clinical
"The primary purpose of this study is to evaluate the efficacy and safety of X-396 (ensartinib) vs. crizotinib in patients with ALK-positive non-small cell lung cancer that have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor."
The cached registry summary supports the eXALT3 comparison and population; active-not-recruiting status was independently verified on 2026-07-18.
{ }

Source YAML

click to show 
name: ALK-Rearranged Non-Small Cell Lung Cancer
creation_date: '2026-01-26T02:55:13Z'
description: >-
  ALK-rearranged non-small cell lung cancer (NSCLC) is a molecular subtype
  defined by a somatic ALK fusion oncoprotein, most commonly EML4::ALK from a
  chromosome 2 inversion. It accounts for a cohort-dependent minority of NSCLC
  and is enriched among younger people and never-smokers, but those demographic
  associations are neither causal mechanisms nor diagnostic criteria.
  Adenocarcinoma is the predominant histology, with rare ALK-rearranged squamous
  cancers reported. ALK tyrosine kinase inhibitors produce substantial systemic
  and intracranial disease control; CNS progression and acquired on-target or
  bypass resistance remain important disease-management challenges.
categories:
- Molecularly-Defined Cancer
- Lung Cancer Subtype
- Fusion Gene-Driven Cancer
- Solid Tumor
parents:
- non-small cell lung carcinoma
synonyms:
- ALK-positive NSCLC
- ALK fusion-positive non-small cell lung cancer
- ALK-rearranged lung cancer
external_assertions:
- name: CIViC ALK fusion crizotinib sensitivity assertion
  source: CIViC
  assertion_type: accepted_assertion
  external_id: CIVIC_ASSERTION:3
  url: https://civicdb.org/links/assertions/3
  description: >-
    CIViC accepted assertion that ALK fusion-positive non-small cell lung
    carcinoma predicts sensitivity/response to crizotinib.
  notes: >-
    01-May-2026 CIViC accepted assertion: molecular_profile="v::ALK Fusion";
    disease="Lung Non-small Cell Carcinoma"; assertion_type=Predictive;
    significance=Sensitivity/Response; therapy=Crizotinib; AMP category=Tier I - Level A.
  evidence:
  - reference: CIVIC_ASSERTION:3
    reference_title: "v::ALK Fusion / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Lung adenocarcinoma positive for ALK-FUSIONS have been found to be sensitive to crizotinib treatment
    explanation: CIViC records an accepted predictive sensitivity assertion for ALK fusion and crizotinib in NSCLC.
- name: CIViC ALK fusion alectinib sensitivity assertion
  source: CIViC
  assertion_type: accepted_assertion
  external_id: CIVIC_ASSERTION:34
  url: https://civicdb.org/links/assertions/34
  description: >-
    CIViC accepted assertion that ALK fusion-positive non-small cell lung
    carcinoma predicts sensitivity/response to alectinib.
  notes: >-
    01-May-2026 CIViC accepted assertion: molecular_profile="v::ALK Fusion";
    disease="Lung Non-small Cell Carcinoma"; assertion_type=Predictive;
    significance=Sensitivity/Response; therapy=Alectinib; AMP category=Tier I - Level A.
  evidence:
  - reference: CIVIC_ASSERTION:34
    reference_title: "v::ALK Fusion / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: ALK fusion positive NSCLC is sensitive to alectinib
    explanation: CIViC records an accepted predictive sensitivity assertion for ALK fusion and alectinib in NSCLC.
- name: CIViC EML4::ALK plus ALK G1202R crizotinib resistance evidence item
  source: CIViC
  assertion_type: accepted_evidence_item
  external_id: CIVIC_EID:441
  url: https://civicdb.org/links/evidence_items/441
  description: >-
    CIViC accepted evidence item linking EML4::ALK fusion with ALK G1202R in
    non-small cell lung cancer to crizotinib resistance.
  notes: >-
    01-May-2026 CIViC accepted evidence item: molecular_profile="EML4::ALK
    Fusion AND ALK G1202R"; evidence_type=Predictive; evidence_level=D;
    significance=Resistance; therapy=Crizotinib; citation_id=PMID:22277784.
  evidence:
  - reference: CIVIC_EID:441
    reference_title: "EML4::ALK Fusion AND ALK G1202R / Lung Non-small Cell Carcinoma (Predictive Resistance)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The G1202R mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.
    explanation: CIViC records an accepted predictive resistance evidence item for ALK G1202R and crizotinib in NSCLC.
epidemiology:
- name: Cohort-dependent ALK-rearrangement frequency
  description: >-
    ALK rearrangements define a minority molecular subtype whose measured
    frequency varies with histology, stage, population, and testing strategy.
    A surgical NSCLC cohort found 3.8%, whereas a large Chinese advanced-NSCLC
    cohort found 6.7%; these selected-cohort proportions are not population
    point-prevalence estimates.
  evidence:
  - reference: PMID:22129856
    reference_title: "Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of the 735 NSCLC cases, 28 (3.8%) were ALK FISH-positive.
    explanation: >-
      This surgical cohort provides a directly measured ALK-positive fraction
      while defining the population and assay used.
  - reference: PMID:39016057
    reference_title: "Real-world data on ALK rearrangement test in Chinese advanced non-small cell lung cancer (RATICAL): a nationwide multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The overall ALK gene rearrangement rate was 6.7% in 23,689 patients with
      advanced NSCLC and 8.2% in 17,436 patients with advanced lung
      adenocarcinoma.
    explanation: >-
      This large advanced-disease cohort demonstrates that molecular-subtype
      fractions depend on the clinical and histologic denominator.
- name: Younger-age and never-smoker enrichment
  description: >-
    ALK-positive NSCLC is enriched among younger patients and never-smokers.
    These are epidemiologic associations, not downstream effects of ALK fusion
    signaling and not substitutes for tumor molecular testing.
  evidence:
  - reference: PMID:22129856
    reference_title: "Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ALK rearrangement was significantly higher in adenocarcinomas (6.8%,
      p<0.001), younger age (p<0.0007), women (7.6%, p<0.001), and never-smokers
      (8.9%, p<0.001) with no gender difference in the adenocarcinoma or
      never-smoker subgroup.
    explanation: >-
      The cohort directly supports age and smoking-status enrichment without
      implying a causal molecular pathway.
  - reference: PMID:39016057
    reference_title: "Real-world data on ALK rearrangement test in Chinese advanced non-small cell lung cancer (RATICAL): a nationwide multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The overall ALK gene rearrangement rates were higher in females, patients
      of ≤ 35 years old, never smokers, tumor cellularity of > 50, and metastatic
      specimens used for testing in the total NSCLC population and adenocarcinoma
      subgroup (all P < 0.05).
    explanation: >-
      The nationwide cohort independently supports the demographic enrichment.
has_subtypes:
- name: EML4::ALK fusion-positive NSCLC
  description: >-
    EML4 is the dominant ALK fusion partner in NSCLC. Different EML4 breakpoints
    create molecular variants; variant 3 may be associated with poorer outcomes
    in pooled studies, but it is not an established treatment-selection marker
    and ALEX did not find variant-specific alectinib efficacy differences.
  evidence:
  - reference: PMID:17625570
    reference_title: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we show that a small inversion within chromosome 2p results in the
      formation of a fusion gene comprising portions of the echinoderm
      microtubule-associated protein-like 4 (EML4) gene and the anaplastic
      lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.
    explanation: >-
      The discovery study identifies the defining EML4::ALK inversion and also
      reports transforming activity in cell and mouse models.
  - reference: PMID:41959926
    reference_title: A meta-analysis of the impact of different ALK variants on targeted therapy efficacy in advanced non-small cell lung cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: V3 was associated with shorter progression-free survival (PFS)
    explanation: >-
      The pooled association supports possible adverse prognostic value but
      does not establish a variant-directed treatment rule.
  - reference: PMID:30902613
    reference_title: "Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      variants 1, 2, and 3/ab did not affect PFS, objective response rate, or
      duration of response.
    explanation: >-
      ALEX bounds the meta-analytic signal by showing no efficacy difference
      across common variants in that alectinib trial.
- name: Other ALK fusion-partner NSCLC
  description: >-
    Less common ALK fusions use partners other than EML4. Published examples
    include KIF5B::ALK, TFG::ALK, and TNIP2::ALK; evidence for response and
    prognosis is partner-specific and much sparser than for EML4::ALK.
  evidence:
  - reference: PMID:31521978
    reference_title: The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ALK rearrangements have been previously identified in about 5.1% of lung
      adenocarcinoma, including EML4-ALK fusion variants, KIF5B-ALK and TFG-ALK.
    explanation: >-
      The report directly names non-EML4 partners but does not establish uniform
      behavior across all rare fusions.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_alk_fusion_mitogenic_signaling_model
  hypothesis_label: Canonical ALK Fusion Mitogenic Signaling Model
  status: CANONICAL
  description: >-
    A somatic ALK fusion creates a constitutively active kinase that assembles
    cytoplasmic signaling foci and sustains MAPK and PI3K-AKT output. The
    resulting ALK-dependent proliferation and survival program drives the
    predominantly adenocarcinoma NSCLC phenotype and creates a targetable
    oncogene dependence. Metastatic progression to the CNS uses additional
    general invasion, dissemination, and colonization steps rather than a
    demonstrated direct ALK-to-brain route.
  evidence:
  - reference: PMID:17625570
    reference_title: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase
      generated transformed foci in culture and subcutaneous tumours in nude
      mice.
    explanation: >-
      The discovery study demonstrates transforming activity of EML4::ALK in
      both cell culture and a mouse tumor model.
  - reference: PMID:20952506
    reference_title: Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      To evaluate potential treatment strategies for lung cancers driven by an
      activated EML4-ALK chimeric oncogene, we generated a genetically engineered
      mouse model that phenocopies the human disease where this rearranged gene
      arises.
    explanation: >-
      The inducible mouse model supports an ALK-fusion-driven lung-tumor program
      while remaining preclinical evidence.
- hypothesis_group_id: acquired_alk_tki_resistance_model
  hypothesis_label: Acquired ALK TKI Resistance Model
  status: CANONICAL
  description: >-
    Exposure to ALK-directed therapy imposes selection pressure that can produce
    on-target ALK kinase-domain mutations or preserve tumor-cell survival through
    adaptive kinase signaling, microenvironmental bypass, and phenotypic state
    changes such as EMT. The existence of these resistance classes is
    established; many specific combination strategies remain preclinical, and no
    single later-generation ALK inhibitor suppresses every bypass or compound
    resistance state.
  evidence:
  - reference: PMID:37149843
    reference_title: "EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      However, resistance to ALK inhibitors can occur via point-mutations within
      the kinase domain of the EML4-ALK fusion, for example G1202R, reducing
      inhibitor effectiveness.
    explanation: >-
      This review supports the established on-target mutation class while not
      implying that all resistance is ALK-dependent.
  - reference: PMID:28676215
    reference_title: "Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We conclude that the T1151K ALK mutation confers resistance to ceritinib,
      which may be rescued by alectinib or lorlatinib as evidenced by this
      clinical narrative.
    explanation: >-
      The patient narrative directly connects sequential ALK-TKI exposure with
      an acquired on-target resistance mutation and differential drug response.
pathophysiology:
- name: ALK fusion oncoprotein formation
  conforms_to: "sustaining_proliferative_signaling#Oncogenic Growth-Signal Lesion"
  role: trigger
  description: >-
    A somatic inversion or translocation preserves the ALK kinase domain and
    joins it to an N-terminal partner. EML4::ALK is the dominant exemplar in
    NSCLC; other partners can create the same disease-defining class without
    necessarily reproducing every EML4-specific assembly property.
  genes:
  - preferred_term: ALK
    term:
      id: hgnc:427
      label: ALK
  - preferred_term: EML4
    term:
      id: hgnc:1316
      label: EML4
  molecular_functions:
  - preferred_term: protein tyrosine kinase activity
    modifier: INCREASED
    term:
      id: GO:0004713
      label: protein tyrosine kinase activity
  evidence:
  - reference: PMID:17625570
    reference_title: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we show that a small inversion within chromosome 2p results in the
      formation of a fusion gene comprising portions of the echinoderm
      microtubule-associated protein-like 4 (EML4) gene and the anaplastic
      lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.
    explanation: >-
      The discovery study directly identifies the chromosome 2 inversion and
      EML4::ALK fusion in NSCLC cells.
  - reference: CIVIC_ASSERTION:3
    reference_title: "v::ALK Fusion / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: ALK-FUSIONS are found in 3-5% of non-small cell lung cancer and act as a targetable driver mutation.
    explanation: >-
      The accepted CIViC assertion independently classifies ALK fusions as
      targetable NSCLC driver alterations.
  downstream:
  - target: Constitutive ALK mitogenic and survival signaling
    causal_link_type: DIRECT
    description: >-
      Fusion-mediated ALK activation produces ligand-independent kinase output
      and constitutive downstream signaling.
    hypothesis_groups:
    - canonical_alk_fusion_mitogenic_signaling_model
    evidence:
    - reference: CIVIC_ASSERTION:34
      reference_title: "v::ALK Fusion / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        These fusions act as driver mutations through ligand-independent
        dimerization of ALK and constitutive downstream pathway activation.
      explanation: >-
        CIViC directly supports the causal link from ALK fusion to constitutive
        signaling while avoiding a universal claim about every partner's
        detailed oligomeric structure.
- name: Constitutive ALK mitogenic and survival signaling
  conforms_to: "sustaining_proliferative_signaling#Constitutive Mitogenic Pathway Activation"
  role: central_effector
  description: >-
    Active EML4::ALK assembles cytoplasmic signaling foci containing MAPK and
    PI3K pathway components. Sustained kinase output engages MEK-ERK and
    PI3K-AKT survival programs; JAK-STAT is not asserted here as a universal
    disease-level branch because the attached evidence is variant- and
    context-dependent.
  biological_processes:
  - preferred_term: Ras protein signal transduction
    modifier: INCREASED
    term:
      id: GO:0007265
      label: Ras protein signal transduction
  - preferred_term: ERK1 and ERK2 cascade
    modifier: INCREASED
    term:
      id: GO:0070371
      label: ERK1 and ERK2 cascade
  - preferred_term: phosphatidylinositol 3-kinase signaling
    modifier: INCREASED
    term:
      id: GO:0043491
      label: phosphatidylinositol 3-kinase/protein kinase B signal transduction
  evidence:
  - reference: PMID:34661367
    reference_title: Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Here, we show that EML4-ALK V1 and V3 proteins form cytoplasmic foci that
      contain components of the MAPK, PLCγ and PI3K signalling pathways.
    explanation: >-
      Cell experiments directly localize core signaling components to
      EML4::ALK assemblies.
  downstream:
  - target: ALK-dependent tumor-cell proliferation and survival
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - PI3K-AKT survival signaling
    - MEK-ERK proliferative signaling
    description: >-
      Persistent ALK output maintains growth and survival through the PI3K-AKT
      and MEK-ERK pathways.
    hypothesis_groups:
    - canonical_alk_fusion_mitogenic_signaling_model
    evidence:
    - reference: PMID:20952506
      reference_title: Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        In H3122 cells, TAE684-mediated ALK inhibition results in downregulation
        of PI3K/AKT and MEK/ERK1/2 signaling, and apoptosis.
      explanation: >-
        Pharmacologic perturbation in EML4::ALK cells links ALK activity to both
        pathway output and cell survival.
- name: ALK-dependent tumor-cell proliferation and survival
  conforms_to: "sustaining_proliferative_signaling#Growth-Factor-Independent Proliferation"
  role: consequence
  description: >-
    ALK-rearranged tumor cells depend on continued fusion-kinase signaling for
    proliferation and survival. This is a targetable oncogene dependence, not a
    claim that ALK expression alone transforms every human lung-cell context.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  - preferred_term: apoptotic process
    modifier: DECREASED
    term:
      id: GO:0006915
      label: apoptotic process
  evidence:
  - reference: PMID:20952506
    reference_title: Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      These findings suggest that EML4-ALK–driven cancers display features of
      oncogene dependence or addiction and that ALK inhibitors may be
      particularly effective for this lung cancer subset.
    explanation: >-
      The preclinical study explicitly frames the ALK-rearranged model as
      oncogene-dependent.
  downstream:
  - target: Lung Adenocarcinoma
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - clonal expansion
    - malignant transformation
    description: >-
      Sustained ALK-dependent proliferation and survival support malignant
      transformation into the predominantly adenocarcinoma NSCLC phenotype.
    hypothesis_groups:
    - canonical_alk_fusion_mitogenic_signaling_model
    evidence:
    - reference: PMID:17625570
      reference_title: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase
        generated transformed foci in culture and subcutaneous tumours in nude
        mice.
      explanation: >-
        The experimental transformation result supports tumorigenic capacity
        while the indirect edge preserves the required intermediate steps.
  - target: Brain Metastases
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - local tumor progression and invasion
    - hematogenous dissemination
    - central nervous system colonization
    description: >-
      ALK-positive lung tumors can progress through the general metastatic
      cascade to clinically frequent brain metastases; an ALK-specific direct
      route to the brain is not asserted.
    hypothesis_groups:
    - canonical_alk_fusion_mitogenic_signaling_model
    evidence:
    - reference: PMID:34147645
      reference_title: "Treatment of brain metastases in ALK-positive non-small cell lung cancer."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Brain metastases are quite frequent in patients with ALK-translocated non-small cell lung cancer (NSCLC)
      explanation: >-
        The review directly supports the clinical endpoint but not a unique
        ALK-specific metastatic mechanism, so support for the causal edge is
        partial.
- name: ALK TKI therapeutic selection pressure
  role: trigger
  description: >-
    ALK-directed therapy suppresses sensitive tumor cells while creating a
    treatment-conditioned selection environment in which resistant on-target
    clones, adaptive signaling programs, microenvironmental rescue, or altered
    cell states can persist and expand. Treatment exposure—not oncogene
    dependence by itself—is the proximal context for acquired resistance.
  biological_processes:
  - preferred_term: response to xenobiotic stimulus
    modifier: ABNORMAL
    term:
      id: GO:0009410
      label: response to xenobiotic stimulus
  evidence:
  - reference: PMID:28676215
    reference_title: "Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we report for the first time a novel ALK T1151K mutation in a patient
      with metastatic ALK-rearranged NSCLC who progressed on crizotinib and then
      ceritinib.
    explanation: >-
      The clinical sequence directly establishes treatment exposure before the
      acquired mutation was detected.
  downstream:
  - target: ALK kinase-domain mutation-mediated resistance
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - survival of mutation-bearing tumor subclones
    - expansion during ALK inhibition
    description: >-
      ALK-TKI pressure can select kinase-domain substitutions that reduce
      inhibitor binding or alter drug-specific sensitivity.
    hypothesis_groups:
    - acquired_alk_tki_resistance_model
    evidence:
    - reference: PMID:28676215
      reference_title: "Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Here we report for the first time a novel ALK T1151K mutation in a
        patient with metastatic ALK-rearranged NSCLC who progressed on
        crizotinib and then ceritinib.
      explanation: >-
        This is direct patient evidence for an acquired on-target mutation after
        sequential ALK-TKI exposure.
  - target: Adaptive kinase-bypass resistance
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - compensatory receptor tyrosine kinase activation
    - restoration of downstream survival signaling
    description: >-
      Resistant cells can restore growth signaling through alternate kinase
      pathways despite continued ALK inhibition.
    hypothesis_groups:
    - acquired_alk_tki_resistance_model
    evidence:
    - reference: PMID:24199682
      reference_title: Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Crizotinib+erlotinib (reversible EGFR TKI) and crizotinib+afatinib
        (irreversible EGFR/ERBB2 TKI) were able to inhibit the growth of H3122 CR
        clones, confirming EGFR activation as a mechanism of resistance.
      explanation: >-
        Resistant-cell experiments demonstrate a compensatory EGFR bypass
        program; clinical benefit from dual inhibition is not inferred.
  - target: Microenvironment-mediated ALK bypass resistance
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - stromal growth-factor or matrix signaling
    - MET-integrin or GAS6-AXL survival output
    description: >-
      Fibroblast- and macrophage-derived signals can preserve resistant tumor
      cell survival through MET, integrin, or GAS6-AXL pathways.
    hypothesis_groups:
    - acquired_alk_tki_resistance_model
    evidence:
    - reference: PMID:41433419
      reference_title: Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Concurrent targeting of MET and integrin signaling effectively abrogated
        ALK inhibitor resistance in EML4-ALK+ NSCLC cells cocultured with CAFs.
      explanation: >-
        The coculture experiment directly supports concurrent stromal MET and
        integrin rescue, while remaining preclinical.
  - target: EMT-associated ALK TKI resistance
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - STAT3-Slug activation
    - epithelial-to-mesenchymal state transition
    description: >-
      In a G1202R cell model, STAT3-Slug signaling accompanies an invasive EMT
      state and reduced ceritinib sensitivity.
    hypothesis_groups:
    - acquired_alk_tki_resistance_model
    evidence:
    - reference: PMID:35085771
      reference_title: EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Here, we demonstrated that the expression of EML4-ALK G1202R mutation in
        A549 cells induced an epithelial-mesenchymal transition (EMT) phenotype
        and significantly increased the migration and invasion abilities.
      explanation: >-
        The cell experiment directly links the G1202R context to EMT and invasive
        behavior without establishing a universal clinical route.
- name: ALK kinase-domain mutation-mediated resistance
  role: effector
  description: >-
    Secondary ALK kinase-domain substitutions can change inhibitor binding or
    ATP competition. G1202R is a solvent-front resistance mutation, while T1151K
    illustrates drug-specific resistance that may retain sensitivity to another
    ALK inhibitor. This node does not assert that a single agent covers all
    compound mutations.
  genes:
  - preferred_term: ALK
    term:
      id: hgnc:427
      label: ALK
  biological_processes:
  - preferred_term: response to xenobiotic stimulus
    modifier: ABNORMAL
    term:
      id: GO:0009410
      label: response to xenobiotic stimulus
  evidence:
  - reference: CIVIC_EID:441
    reference_title: "EML4::ALK Fusion AND ALK G1202R / Lung Non-small Cell Carcinoma (Predictive Resistance)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The G1202R mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.
    explanation: >-
      The accepted CIViC evidence item provides a bounded cell-model assertion
      for G1202R-mediated crizotinib resistance.
  - reference: PMID:28676215
    reference_title: "Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We conclude that the T1151K ALK mutation confers resistance to ceritinib,
      which may be rescued by alectinib or lorlatinib as evidenced by this
      clinical narrative.
    explanation: >-
      This patient report demonstrates drug-specific sensitivity rather than
      uniform class resistance.
- name: Adaptive kinase-bypass resistance
  role: effector
  mechanism_confidence: PROVISIONAL
  description: >-
    Resistant tumor cells can restore survival output through alternate
    receptor or intracellular kinases, including EGFR and SRC. The attached
    perturbation evidence is preclinical, so proposed combination strategies
    are not represented as established care.
  biological_processes:
  - preferred_term: cell surface receptor protein tyrosine kinase signaling pathway
    modifier: INCREASED
    term:
      id: GO:0007169
      label: cell surface receptor protein tyrosine kinase signaling pathway
  evidence:
  - reference: PMID:24199682
    reference_title: Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We identified activation of EGFR as a mechanism of resistance to
      crizotinib in preclinical models of ALK translocated NSCLC.
    explanation: >-
      The authors explicitly bound the EGFR result to preclinical resistant
      models.
  - reference: PMID:38521003
    reference_title: Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Co-targeting of ALK and SRC showed remarkable inhibitory effects
    explanation: >-
      Cell-model co-targeting supports SRC as a candidate bypass dependency,
      not a clinically validated combination.
- name: Microenvironment-mediated ALK bypass resistance
  role: effector
  mechanism_confidence: PROVISIONAL
  description: >-
    Cancer-associated fibroblasts and tumor-associated macrophages can supply
    paracrine or matrix-associated signals that maintain resistant-cell survival
    through MET-integrin or GAS6-AXL pathways.
  biological_processes:
  - preferred_term: cell surface receptor protein tyrosine kinase signaling pathway
    modifier: INCREASED
    term:
      id: GO:0007169
      label: cell surface receptor protein tyrosine kinase signaling pathway
  evidence:
  - reference: PMID:41433419
    reference_title: Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Concurrent targeting of MET and integrin signaling effectively abrogated
      ALK inhibitor resistance in EML4-ALK+ NSCLC cells cocultured with CAFs.
    explanation: >-
      The coculture perturbation directly supports a stromal MET-integrin rescue
      mechanism.
  - reference: PMID:39904499
    reference_title: AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These findings suggest that AXL expression in resistant cancer cells,
      combined with increased Gas6 production in the TME, contributes to
      enhanced ALK-TKI resistance.
    explanation: >-
      The study combines tumor and microenvironment models to support a
      GAS6-AXL resistance axis.
- name: EMT-associated ALK TKI resistance
  role: effector
  mechanism_confidence: PROVISIONAL
  description: >-
    In an EML4::ALK G1202R cell model, STAT3-Slug activation induces an
    epithelial-to-mesenchymal state with increased migration and invasion and
    reduced ceritinib sensitivity. Its prevalence and treatment implications in
    patients remain unresolved.
  biological_processes:
  - preferred_term: epithelial to mesenchymal transition
    modifier: INCREASED
    term:
      id: GO:0001837
      label: epithelial to mesenchymal transition
  evidence:
  - reference: PMID:35085771
    reference_title: EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In conclusion, these data indicate that the EML4-ALK G1202R mutation
      mediates the EMT phenotype by activating the STAT3/Slug signaling pathway,
      resulting in resistance to ceritinib
    explanation: >-
      The conclusion directly supports the bounded G1202R-STAT3-Slug cell-model
      branch.
histopathology:
- name: Adenocarcinoma-predominant morphology
  finding_term:
    preferred_term: lung adenocarcinoma
    term:
      id: NCIT:C3512
      label: Lung Adenocarcinoma
  description: >-
    ALK-rearranged NSCLC is enriched in adenocarcinoma and can show acinar,
    cribriform, or solid growth, mucin production, and signet-ring-cell elements.
    Rare molecularly confirmed ALK-rearranged squamous carcinomas prevent an
    exclusive-adenocarcinoma formulation.
  evidence:
  - reference: PMID:22129856
    reference_title: "Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Similar to EGFR-mutated lung cancer, ALK-rearranged lung cancer was
      enriched in adenocarcinoma, women, and never-smokers.
    explanation: >-
      This ALK-specific cohort supports adenocarcinoma enrichment without an
      unsupported universal frequency band.
  - reference: PMID:26095438
    reference_title: Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Acinar, cribriform, and solid growth patterns, extracellular and
      intracellular mucin production, and presence of signet-ring-cell element,
      and psammoma body were significantly more often present in ALK-positive
      cancer.
    explanation: >-
      Direct histologic comparison supports the morphology described for
      ALK-positive pulmonary adenocarcinoma.
  - reference: PMID:40783309
    reference_title: Clinical Outcomes of Patients With Advanced ALK-Rearranged Lung Squamous Cell Carcinoma Treated With ALK Tyrosine Kinase Inhibitors.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DNA-based next-generation sequencing (NGS) has identified ALK
      rearrangements in lung squamous cell carcinoma (LUSC), a subset of
      nonsmall cell lung cancer traditionally lacking effective targeted
      therapies.
    explanation: >-
      This recent cohort establishes the rare squamous exception but does not
      quantify its frequency among all ALK-positive cancers.

phenotypes:
- category: Neoplastic
  name: Lung Adenocarcinoma
  description: >-
    Adenocarcinoma is the predominant clinical tumor phenotype of
    ALK-rearranged NSCLC, although rare ALK-rearranged squamous tumors occur.
  phenotype_term:
    preferred_term: Lung adenocarcinoma
    term:
      id: HP:0030078
      label: Lung adenocarcinoma
  evidence:
  - reference: PMID:22129856
    reference_title: "Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ALK rearrangement was significantly higher in adenocarcinomas (6.8%,
      p<0.001)
    explanation: >-
      The ALK-specific surgical cohort supports the predominant adenocarcinoma
      phenotype while not excluding other NSCLC histologies.
- category: Clinical
  name: Brain Metastases
  frequency: FREQUENT
  description: >-
    Brain metastases are a frequent manifestation of advanced ALK-translocated
    NSCLC. Treatment-specific intracranial efficacy is represented under the
    relevant ALK inhibitors rather than as phenotype evidence.
  phenotype_term:
    preferred_term: Brain metastasis
    term:
      id: HP:0030692
      label: Brain neoplasm
  evidence:
  - reference: PMID:34147645
    reference_title: "Treatment of brain metastases in ALK-positive non-small cell lung cancer."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Brain metastases are quite frequent in patients with ALK-translocated non-small cell lung cancer (NSCLC)
    explanation: >-
      The review directly supports frequent brain metastasis as a clinical
      manifestation.
diagnosis:
- name: Tumor ALK fusion testing
  presence: REQUIRED_FOR_SUBTYPE_ASSIGNMENT
  description: >-
    Classification as ALK-rearranged NSCLC requires demonstration of ALK
    positivity in tumor material. Immunohistochemistry, break-apart FISH, and
    DNA- or RNA-based next-generation sequencing provide complementary protein,
    rearrangement, and expressed-fusion readouts. Discordant or complex results
    may require orthogonal confirmation; demographic enrichment is not an
    adequate substitute for testing.
  results: Detection of an oncogenic ALK rearrangement, fusion transcript, or fusion-protein expression
  markers: ALK rearrangement; expressed ALK fusion; ALK protein expression
  evidence:
  - reference: PMID:35624360
    reference_title: Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The concordance rates were 97.1% (34/35) for RNA-NGS, 94.7% (36/38) for
      IHC, and 97.4% (37/38) for FISH.
    explanation: >-
      Direct method comparison supports the complementary use and high, but not
      perfect, concordance of molecular and protein assays.
  - reference: PMID:37190044
    reference_title: "Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: targeted RNA NGS was confirmed to be the most efficient technique for gene fusion identification in clinical practice
    explanation: >-
      The prospective multicenter comparison supports RNA-based fusion
      identification in routine practice.
  - reference: PMID:39016057
    reference_title: "Real-world data on ALK rearrangement test in Chinese advanced non-small cell lung cancer (RATICAL): a nationwide multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      IHC-VENTANA-D5F3 was used in 53.6%, real-time polymerase chain reaction
      (RT-PCR) in 25.4%, next-generation sequencing (NGS) in 18.3%, and
      fluorescence in-situ hybridization (FISH) in 15.9% in the adenocarcinoma
      subgroup.
    explanation: >-
      The real-world cohort demonstrates multimodal ALK testing rather than a
      single universally sufficient assay workflow.
genetic:
- name: ALK
  gene_term:
    preferred_term: ALK
    term:
      id: hgnc:427
      label: ALK
  association: Somatic Rearrangement
  variant_origin: SOMATIC
  relationship_type: SOMATIC_DRIVER
  notes: >-
    ALK (2p23.2) encodes anaplastic lymphoma kinase, a receptor tyrosine kinase.
    A somatic chromosome 2 inversion creates the common EML4::ALK fusion; other
    somatic partner rearrangements also retain the ALK kinase domain. Secondary
    ALK kinase-domain mutations can emerge under ALK-inhibitor selection.
  evidence:
  - reference: PMID:17625570
    reference_title: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a small inversion within chromosome 2p results in the formation of a
      fusion gene comprising portions of the echinoderm microtubule-associated
      protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene
    explanation: >-
      The discovery study directly identifies the somatic chromosome 2 event
      joining EML4 and ALK in NSCLC cells.
  - reference: CIVIC_ASSERTION:3
    reference_title: "v::ALK Fusion / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: ALK-FUSIONS are found in 3-5% of non-small cell lung cancer and act as a targetable driver mutation.
    explanation: CIViC's accepted assertion supports ALK fusions as defining, targetable genetic drivers in NSCLC.
- name: EML4
  gene_term:
    preferred_term: EML4
    term:
      id: hgnc:1316
      label: EML4
  association: Fusion Partner
  variant_origin: SOMATIC
  relationship_type: SOMATIC_DRIVER
  notes: >-
    EML4 (2p21) encodes echinoderm microtubule-associated protein-like 4.
    Its N-terminal portion joins the ALK kinase domain in the canonical
    EML4::ALK oncoprotein. Multiple transcript variants reflect different EML4
    breakpoints and should not be treated as established therapy-selection
    biomarkers.
  evidence:
  - reference: PMID:17625570
    reference_title: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a small inversion within chromosome 2p results in the formation of a
      fusion gene comprising portions of the echinoderm microtubule-associated
      protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene
    explanation: >-
      The original report directly identifies EML4 as the fusion partner in
      the transforming EML4::ALK lesion.
treatments:
- name: Alectinib
  description: >-
    A second-generation ALK inhibitor used in advanced ALK-positive NSCLC and,
    in a distinct disease setting, as adjuvant therapy after complete resection.
    In ALEX it prolonged progression-free survival relative to crizotinib; in
    ALINA it improved disease-free survival relative to platinum chemotherapy
    for resected stage IB (tumors at least 4 cm), II, or IIIA disease. Overall
    survival data from ALINA were immature in the cited analysis.
  target_mechanisms:
  - target: Constitutive ALK mitogenic and survival signaling
    treatment_effect: INHIBITS
    description: >-
      Alectinib (CH5424802) inhibits ALK kinase activity and suppresses growth
      driven by EML4::ALK.
    evidence:
    - reference: PMID:21575866
      reference_title: "CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        showing preferential antitumor activity against cancers with gene
        alterations of ALK, such as nonsmall cell lung cancer (NSCLC) cells
        expressing EML4-ALK fusion
      explanation: >-
        Preclinical data directly support inhibition of the ALK-dependent
        growth program represented by this target node.
  pdb_structures:
  - pdb_id: 3AOX
    description: >-
      Wild-type ALK kinase domain in complex with CH5424802 (alectinib); this
      structure should not be interpreted as a mutant co-crystal.
    resolution_angstrom: 1.75
    method: X-ray
    ligand: alectinib
    target_protein: ALK (anaplastic lymphoma kinase)
    publication: PMID:21575866
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: alectinib
      term:
        id: CHEBI:90936
        label: alectinib
  evidence:
  - reference: PMID:30902613
    reference_title: Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median PFS times were 34.8 months with alectinib and 10.9 months with
      crizotinib.
    explanation: >-
      The updated randomized ALEX analysis directly supports longer
      progression-free survival with first-line alectinib.
  - reference: PMID:38598794
    reference_title: Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: adjuvant alectinib significantly improved disease-free survival
    explanation: >-
      ALINA directly supports the separate adjuvant indication after complete
      resection of stage IB-IIIA ALK-positive NSCLC.
  - reference: CIVIC_ASSERTION:34
    reference_title: "v::ALK Fusion / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: ALK fusion positive NSCLC is sensitive to alectinib
    explanation: CIViC's accepted assertion directly supports alectinib sensitivity in ALK fusion-positive NSCLC.
- name: Lorlatinib
  description: >-
    A third-generation, brain-penetrant ALK inhibitor used for advanced
    ALK-positive NSCLC. Seven-year CROWN follow-up showed durable systemic and
    intracranial control relative to crizotinib. Preclinical data support
    activity across wild-type ALK and multiple single kinase-domain resistance
    mutations; this does not imply control of bypass signaling or every compound
    mutation.
  target_mechanisms:
  - target: Constitutive ALK mitogenic and survival signaling
    treatment_effect: INHIBITS
    description: >-
      Lorlatinib inhibits the ALK kinase program maintained by the fusion
      oncoprotein.
    evidence:
    - reference: PMID:24819116
      reference_title: "Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        These structurally unusual macrocyclic inhibitors were potent against
        wild-type ALK and clinically reported ALK kinase domain mutations.
      explanation: >-
        The lorlatinib discovery study directly supports inhibition of
        wild-type fusion-driven ALK signaling.
  - target: ALK kinase-domain mutation-mediated resistance
    treatment_effect: INHIBITS
    description: >-
      Lorlatinib retains preclinical potency against multiple clinically
      reported single ALK kinase-domain mutations.
    evidence:
    - reference: PMID:24819116
      reference_title: "Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        These structurally unusual macrocyclic inhibitors were potent against
        wild-type ALK and clinically reported ALK kinase domain mutations.
      explanation: >-
        The preclinical evidence supports an on-target resistance link while
        not extending the claim to bypass or all compound resistance states.
  pdb_structures:
  - pdb_id: 4CLI
    description: >-
      Wild-type ALK kinase domain in complex with PF-06463922 (lorlatinib); the
      entry is not a G1202R mutant co-crystal.
    resolution_angstrom: 2.05
    method: X-ray
    ligand: lorlatinib
    target_protein: ALK (anaplastic lymphoma kinase)
    publication: PMID:24819116
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: lorlatinib
      term:
        id: CHEBI:143117
        label: lorlatinib
  evidence:
  - reference: PMID:42217582
    reference_title: "Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 7-year PFS was 55% and 3%, respectively.
    explanation: >-
      The mature CROWN update directly supports durable first-line benefit over
      crizotinib; overall-survival follow-up remained ongoing.
- name: Ceritinib
  description: >-
    A second-generation ALK inhibitor with randomized first-line evidence in
    advanced ALK-rearranged nonsquamous NSCLC. ASCEND-4 showed longer
    progression-free survival than platinum/pemetrexed chemotherapy.
  target_mechanisms:
  - target: Constitutive ALK mitogenic and survival signaling
    treatment_effect: INHIBITS
    description: >-
      Clinical selection by ALK rearrangement and randomized benefit support
      inhibition of the fusion-driven ALK signaling program.
    evidence:
    - reference: PMID:28126333
      reference_title: "First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        First-line ceritinib showed a statistically significant and clinically
        meaningful improvement in progression-free survival versus chemotherapy
        in patients with advanced ALK-rearranged NSCLC.
      explanation: >-
        The biomarker-selected randomized trial supports therapeutic inhibition
        of the ALK-dependent disease mechanism.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: ceritinib
      term:
        id: CHEBI:78432
        label: ceritinib
  evidence:
  - reference: PMID:28126333
    reference_title: "First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Median progression-free survival (as assessed by blinded independent
      review committee) was 16·6 months (95% CI 12·6-27·2) in the ceritinib
      group and 8·1 months (5·8-11·1) in the chemotherapy group
    explanation: >-
      ASCEND-4 directly quantifies the progression-free-survival advantage of
      first-line ceritinib over chemotherapy.
- name: Ensartinib
  description: >-
    An oral ALK inhibitor evaluated as first-line therapy for advanced
    ALK-positive NSCLC. In the phase III eXALT3 trial, ensartinib prolonged
    progression-free survival and improved intracranial response relative to
    crizotinib.
  target_mechanisms:
  - target: Constitutive ALK mitogenic and survival signaling
    treatment_effect: INHIBITS
    description: >-
      Ensartinib is an ALK tyrosine-kinase inhibitor tested in molecularly
      selected ALK-positive tumors.
    evidence:
    - reference: PMID:34473194
      reference_title: "Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Ensartinib, an oral tyrosine kinase inhibitor of anaplastic lymphoma
        kinase (ALK), has shown systemic and central nervous system efficacy for
        patients with ALK-positive non-small cell lung cancer (NSCLC).
      explanation: >-
        The randomized study directly identifies ensartinib as an ALK inhibitor
        and supports its link to the fusion-driven signaling target.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: ensartinib hydrochloride
      term:
        id: NCIT:C171676
        label: Ensartinib Hydrochloride
  evidence:
  - reference: PMID:34473194
    reference_title: "Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this randomized clinical trial, ensartinib showed superior efficacy to
      crizotinib in both systemic and intracranial disease.
    explanation: >-
      eXALT3 directly supports improved first-line progression-free survival
      with ensartinib relative to crizotinib.
- name: Brigatinib
  description: >-
    A second-generation ALK inhibitor with randomized first-line evidence in
    advanced ALK-positive NSCLC. Final ALTA-1L results showed longer
    progression-free survival than crizotinib; overall survival was not reached
    in either group in that analysis.
  target_mechanisms:
  - target: Constitutive ALK mitogenic and survival signaling
    treatment_effect: INHIBITS
    description: >-
      Clinical selection by ALK positivity and randomized benefit support
      inhibition of the fusion-driven ALK signaling program.
    evidence:
    - reference: PMID:34537440
      reference_title: "Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Brigatinib exhibited superior efficacy compared with crizotinib
        regardless of EML4-ALK variant and TP53 mutation.
      explanation: >-
        The biomarker-selected trial supports brigatinib acting against the
        ALK-dependent disease program without claiming universal mutation coverage.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: brigatinib
      term:
        id: CHEBI:232810
        label: brigatinib
  evidence:
  - reference: PMID:34537440
    reference_title: "Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the ALTA-1L final analysis, with longer follow-up, brigatinib continued
      to exhibit superior efficacy and tolerability versus crizotinib in
      patients with or without poor prognostic biomarkers.
    explanation: >-
      Final ALTA-1L results directly support improved progression-free survival
      with brigatinib relative to crizotinib.
- name: Crizotinib
  description: >-
    The first ALK inhibitor to establish randomized clinical benefit in
    advanced ALK-positive NSCLC. PROFILE 1014 showed longer progression-free
    survival than platinum/pemetrexed chemotherapy. It remains historically
    foundational while later-generation inhibitors provide other options.
  target_mechanisms:
  - target: Constitutive ALK mitogenic and survival signaling
    treatment_effect: INHIBITS
    description: >-
      Crizotinib occupies the ATP-binding cleft of the ALK kinase domain,
      inhibiting the constitutive oncogenic signaling driven by ALK fusions.
    evidence:
    - reference: PMID:21812414
      reference_title: "Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        the clinical candidate crizotinib (PF-02341066), which demonstrated
        potent in vitro and in vivo c-MET kinase and ALK inhibition
      explanation: >-
        The drug-discovery study directly supports ALK inhibition by
        crizotinib.
  pdb_structures:
  - pdb_id: 2XP2
    description: >-
      Wild-type human ALK kinase domain in complex with crizotinib; this entry
      is distinct from the c-MET structure used earlier in structure-guided
      development.
    resolution_angstrom: 1.9
    method: X-ray
    ligand: crizotinib
    target_protein: ALK (anaplastic lymphoma kinase)
    publication: PMID:21812414
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: crizotinib
      term:
        id: CHEBI:64310
        label: crizotinib
  evidence:
  - reference: PMID:25470694
    reference_title: First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Crizotinib was superior to standard first-line
      pemetrexed-plus-platinum chemotherapy in patients with previously
      untreated advanced ALK-positive NSCLC.
    explanation: >-
      PROFILE 1014 directly supports first-line crizotinib efficacy in advanced
      ALK-positive NSCLC.
  - reference: CIVIC_ASSERTION:3
    reference_title: "v::ALK Fusion / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Lung adenocarcinoma positive for ALK-FUSIONS have been found to be sensitive to crizotinib treatment
    explanation: CIViC's accepted assertion directly supports crizotinib sensitivity in ALK fusion-positive NSCLC.
- name: Platinum/pemetrexed chemotherapy
  description: >-
    Platinum plus pemetrexed is a studied cytotoxic regimen in advanced
    ALK-positive NSCLC. Its placement in an individual treatment sequence
    depends on stage, prior therapy, comorbidity, and current guidance and is
    not inferred from the retrospective cohort cited here.
  treatment_term:
    preferred_term: Chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
  evidence:
  - reference: PMID:22887466
    reference_title: "Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among 70 ALK-positive patients treated with a platinum/pemetrexed regimen, the median PFS (mPFS) was 7.3 months
    explanation: Directly supports platinum/pemetrexed chemotherapy as a studied regimen in advanced ALK-positive NSCLC.
disease_term:
  preferred_term: non-small cell lung carcinoma
  term:
    id: MONDO:0005233
    label: non-small cell lung carcinoma

classifications:
  icdo_morphology:
    classification_value: Carcinoma
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
clinical_trials:
- name: NCT02075840
  phase: PHASE_III
  status: COMPLETED
  description: >-
    ALEX phase III trial comparing first-line alectinib with crizotinib in
    advanced ALK-positive NSCLC.
  evidence:
  - reference: clinicaltrials:NCT02075840
    reference_title: "Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This randomized, active controlled, multicenter phase III open-label study
      is designed to evaluate the efficacy and safety of alectinib compared with
      crizotinib treatment in participants with treatment-naive anaplastic
      lymphoma kinase-positive (ALK-positive) advanced non-small cell lung
      cancer (NSCLC).
    explanation: >-
      The cached registry summary supports the ALEX design and population;
      completion status was independently verified against the live registry on
      2026-07-18.
- name: NCT03052608
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: >-
    CROWN phase III trial comparing first-line lorlatinib with crizotinib in
    advanced ALK-positive NSCLC.
  evidence:
  - reference: clinicaltrials:NCT03052608
    reference_title: "A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A phase 3 study to demonstrate whether lorlatinib given as monotherapy is
      superior to crizotinib alone in prolonging the progression-free survival
      in advanced ALK-positive NSCLC patients who are treatment naïve and to
      compare lorlatinib to crizotinib with respect to overall survival in the
      same population
    explanation: >-
      The cached registry summary supports the CROWN design and endpoints;
      active-not-recruiting status was independently verified on 2026-07-18.
- name: NCT03456076
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: >-
    ALINA phase III trial comparing adjuvant alectinib with platinum-based
    chemotherapy after complete resection.
  evidence:
  - reference: clinicaltrials:NCT03456076
    reference_title: "A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This randomized, active-controlled, multicenter, open-label, Phase III
      study is designed to investigate the efficacy and safety of alectinib
      compared with platinum-based in the adjuvant setting.
    explanation: >-
      The cached registry summary supports the ALINA adjuvant comparison;
      active-not-recruiting status was independently verified on 2026-07-18.
- name: NCT01828099
  phase: PHASE_III
  status: COMPLETED
  description: >-
    ASCEND-4 phase III trial comparing first-line ceritinib with
    platinum-pemetrexed chemotherapy.
  evidence:
  - reference: clinicaltrials:NCT01828099
    reference_title: "A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To compare the efficacy and safety of ceritinib with standard first-line
      chemotherapy (pemetrexed plus cisplatin or carboplatin) in patients with
      stage IIIB (not candidates for definitive multimodality therapy) or stage
      IV, non-squamous non-small cell lung cancer (NSCLC) harboring a confirmed
      anaplastic lymphoma kinase (ALK) rearrangement, using the Ventana
      immunohistochemistry (IHC) test.
    explanation: >-
      The cached registry summary supports the ASCEND-4 design and population;
      completion status was independently verified on 2026-07-18.
- name: NCT02737501
  phase: PHASE_III
  status: COMPLETED
  description: >-
    ALTA-1L phase III trial comparing first-line brigatinib with crizotinib in
    advanced ALK-positive NSCLC.
  evidence:
  - reference: clinicaltrials:NCT02737501
    reference_title: "A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The purpose of the study is to compare the efficacy of brigatinib to that
      of crizotinib in ALK+ locally advanced or metastatic non-small cell lung
      cancer (NSCLC) participants naive to ALK inhibitors, as evidenced by
      progression-free survival (PFS).
    explanation: >-
      The cached registry summary supports the ALTA-1L comparison and endpoint;
      completion status was independently verified on 2026-07-18.
- name: NCT01154140
  phase: PHASE_III
  status: COMPLETED
  description: >-
    PROFILE 1014 phase III trial comparing first-line crizotinib with
    platinum-pemetrexed chemotherapy.
  evidence:
  - reference: clinicaltrials:NCT01154140
    reference_title: "Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study will evaluate the anti-cancer effects of crizotinib when
      compared with standard chemotherapy in patients with ALK positive lung
      cancer.
    explanation: >-
      The cached registry summary supports the PROFILE 1014 comparison;
      completion status was independently verified on 2026-07-18.
- name: NCT02767804
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: >-
    eXALT3 phase III trial comparing ensartinib with crizotinib in ALK-positive
    NSCLC.
  evidence:
  - reference: clinicaltrials:NCT02767804
    reference_title: "Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The primary purpose of this study is to evaluate the efficacy and safety
      of X-396 (ensartinib) vs. crizotinib in patients with ALK-positive
      non-small cell lung cancer that have received up to 1 prior chemotherapy
      regimen and no prior ALK inhibitor.
    explanation: >-
      The cached registry summary supports the eXALT3 comparison and population;
      active-not-recruiting status was independently verified on 2026-07-18.
references:
- reference: "CIVIC_ASSERTION:3"
  title: "v::ALK Fusion / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
- reference: "CIVIC_ASSERTION:34"
  title: "v::ALK Fusion / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
- reference: "CIVIC_EID:441"
  title: "EML4::ALK Fusion AND ALK G1202R / Lung Non-small Cell Carcinoma (Predictive Resistance)"
- reference: "PMID:17625570"
  title: "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer."
- reference: "PMID:20952506"
  title: "Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene."
- reference: "PMID:21575866"
  title: "CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant."
- reference: "PMID:21812414"
  title: "Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)."
- reference: "PMID:22129856"
  title: "Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma."
- reference: "PMID:22887466"
  title: "Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer."
- reference: "PMID:24199682"
  title: "Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer."
- reference: "PMID:24819116"
  title: "Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations."
- reference: "PMID:25470694"
  title: "First-line crizotinib versus chemotherapy in ALK-positive lung cancer."
- reference: "PMID:26095438"
  title: "Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma."
- reference: "PMID:28126333"
  title: "First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study."
- reference: "PMID:28676215"
  title: "Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib."
- reference: "PMID:30902613"
  title: "Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study."
- reference: "PMID:31521978"
  title: "The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma."
- reference: "PMID:34147645"
  title: "Treatment of brain metastases in ALK-positive non-small cell lung cancer."
- reference: "PMID:34473194"
  title: "Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial."
- reference: "PMID:34537440"
  title: "Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial."
- reference: "PMID:34661367"
  title: "Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation."
- reference: "PMID:35085771"
  title: "EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling."
- reference: "PMID:35624360"
  title: "Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer."
- reference: "PMID:37149843"
  title: "EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries."
- reference: "PMID:37190044"
  title: "Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?"
- reference: "PMID:38521003"
  title: "Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome."
- reference: "PMID:38598794"
  title: "Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer."
- reference: "PMID:39016057"
  title: "Real-world data on ALK rearrangement test in Chinese advanced non-small cell lung cancer (RATICAL): a nationwide multicenter retrospective study."
- reference: "PMID:39904499"
  title: "AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts."
- reference: "PMID:40783309"
  title: "Clinical Outcomes of Patients With Advanced ALK-Rearranged Lung Squamous Cell Carcinoma Treated With ALK Tyrosine Kinase Inhibitors."
- reference: "PMID:41433419"
  title: "Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling."
- reference: "PMID:41959926"
  title: "A meta-analysis of the impact of different ALK variants on targeted therapy efficacy in advanced non-small cell lung cancer."
- reference: "PMID:42217582"
  title: "Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study."
- reference: "clinicaltrials:NCT01154140"
  title: "Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus."
- reference: "clinicaltrials:NCT01828099"
  title: "A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer"
- reference: "clinicaltrials:NCT02075840"
  title: "Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer"
- reference: "clinicaltrials:NCT02737501"
  title: "A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer"
- reference: "clinicaltrials:NCT02767804"
  title: "Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients"
- reference: "clinicaltrials:NCT03052608"
  title: "A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER"
- reference: "clinicaltrials:NCT03456076"
  title: "A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer"
📚

References & Deep Research

References

40
CIVIC_ASSERTION:3
v::ALK Fusion / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)
No top-level findings curated for this source.
CIVIC_ASSERTION:34
v::ALK Fusion / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)
No top-level findings curated for this source.
CIVIC_EID:441
EML4::ALK Fusion AND ALK G1202R / Lung Non-small Cell Carcinoma (Predictive Resistance)
No top-level findings curated for this source.
PMID:17625570
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
No top-level findings curated for this source.
PMID:20952506
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
No top-level findings curated for this source.
PMID:21575866
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
No top-level findings curated for this source.
PMID:21812414
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
No top-level findings curated for this source.
PMID:22129856
Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
No top-level findings curated for this source.
PMID:22887466
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.
No top-level findings curated for this source.
PMID:24199682
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
No top-level findings curated for this source.
PMID:24819116
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
No top-level findings curated for this source.
PMID:25470694
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
No top-level findings curated for this source.
PMID:26095438
Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma.
No top-level findings curated for this source.
PMID:28126333
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
No top-level findings curated for this source.
PMID:28676215
Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.
No top-level findings curated for this source.
PMID:30902613
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
No top-level findings curated for this source.
PMID:31521978
The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
No top-level findings curated for this source.
PMID:34147645
Treatment of brain metastases in ALK-positive non-small cell lung cancer.
No top-level findings curated for this source.
PMID:34473194
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
No top-level findings curated for this source.
PMID:34537440
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
No top-level findings curated for this source.
PMID:34661367
Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation.
No top-level findings curated for this source.
PMID:35085771
EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.
No top-level findings curated for this source.
PMID:35624360
Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer.
No top-level findings curated for this source.
PMID:37149843
EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
No top-level findings curated for this source.
PMID:37190044
Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?
No top-level findings curated for this source.
PMID:38521003
Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome.
No top-level findings curated for this source.
PMID:38598794
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
No top-level findings curated for this source.
PMID:39016057
Real-world data on ALK rearrangement test in Chinese advanced non-small cell lung cancer (RATICAL): a nationwide multicenter retrospective study.
No top-level findings curated for this source.
PMID:39904499
AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts.
No top-level findings curated for this source.
PMID:40783309
Clinical Outcomes of Patients With Advanced ALK-Rearranged Lung Squamous Cell Carcinoma Treated With ALK Tyrosine Kinase Inhibitors.
No top-level findings curated for this source.
PMID:41433419
Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling.
No top-level findings curated for this source.
PMID:41959926
A meta-analysis of the impact of different ALK variants on targeted therapy efficacy in advanced non-small cell lung cancer.
No top-level findings curated for this source.
PMID:42217582
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.
No top-level findings curated for this source.
clinicaltrials:NCT01154140
Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus.
No top-level findings curated for this source.
clinicaltrials:NCT01828099
A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer
No top-level findings curated for this source.
clinicaltrials:NCT02075840
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
No top-level findings curated for this source.
clinicaltrials:NCT02737501
A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
No top-level findings curated for this source.
clinicaltrials:NCT02767804
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
No top-level findings curated for this source.
clinicaltrials:NCT03052608
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER
No top-level findings curated for this source.
clinicaltrials:NCT03456076
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
No top-level findings curated for this source.

Deep Research

3
Disorder ▸

Disorder

  • Name: ALK-Rearranged Non-Small Cell Lung Cancer
  • Category:
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 6

Key Pathophysiology Nodes

  • ALK Gene Rearrangement
  • Constitutive ALK Signaling
  • Oncogene Addiction
  • ALK TKI Resistance
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1177/03008916231202149
  • DOI:10.3389/fimmu.2025.1515748
  • DOI:10.3390/biomedicines12020297
  • DOI:10.3390/ijms26010308
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 18 citations 2026-01-24T18:51:59.968998

Disease Pathophysiology Research Report

Target Disease - Disease Name: ALK-Rearranged Non-Small Cell Lung Cancer (NSCLC) - MONDO ID: Not retrieved in this evidence set - Category: Thoracic oncology; lung adenocarcinoma subtype driven by ALK gene rearrangements

Plan (concise) 1) Aggregate recent primary reviews and mechanistic studies (emphasis 2023–2024). 2) Extract core pathophysiology, downstream signaling, cellular programs, TME features, co-alterations, resistance mechanisms, and clinical correlates. 3) Compile ontology-grounded annotations. 4) Synthesize progression and phenotype links. 5) Produce tables for ontology mapping and provide fully cited narrative. (testa2024alkrearrangedlungadenocarcinoma pages 1-2, parvaresh2024unravelingthepotential pages 24-27, lucia2025nonsmallcelllung pages 2-3)

Pathophysiology description (narrative) Definition and driver biology ALK-rearranged NSCLC is defined by chromosomal rearrangements that fuse the ALK tyrosine kinase domain to partner genes, most commonly EML4, creating a ligand-independent oncoprotein that constitutively activates receptor tyrosine kinase signaling and drives lung adenocarcinogenesis (approx. 2–8% of LUAD; commonly 2–3%) (Testa et al., Tumori, 2024; DOI:10.1177/03008916231202149; URL: https://doi.org/10.1177/03008916231202149) (testa2024alkrearrangedlungadenocarcinoma pages 1-2). “EML4-ALK arises from different EML4 breakpoints producing main variants—variant 1, variant 2, and variant 3” with variant architecture influencing stability and localization (testa2024alkrearrangedlungadenocarcinoma pages 1-2). Variant biology shapes oncogenic output: all variants retain EML4’s trimerization domain enabling ALK autophosphorylation; V1/V2 have incomplete TAPE domains (HSP90 dependency), whereas V3 is a short variant that co-localizes with microtubules and shows distinct signaling condensates (bioRxiv summary, 2025, variant overview) (jimenez2025unravelingtherapeuticstrategies pages 31-34).

Downstream molecular pathways EML4-ALK engages canonical RTK cascades that mediate proliferation, survival, motility, and adaptive resistance, notably: RAS/RAF/MEK/ERK (MAPK), PI3K/AKT/mTOR, JAK/STAT (especially STAT3), and PLCγ-driven DAG/IP3 signaling; adaptor proteins (e.g., GRB2, SHC, IRS-1) propagate these signals (2024–2025 reviews) (jimenez2025unravelingtherapeuticstrategies pages 28-31, parvaresh2024unravelingthepotential pages 9-11). Preclinical and integrative reviews emphasize that co-inhibition of ALK with MEK or STAT3 can lower survivin, increase BIM, and resensitize resistant cells; ALK post-translational methylation by SMYD2 promotes downstream AKT activation and can be blocked to reduce ALK phosphorylation and tumor growth (Biomedicines, 2024; DOI:10.3390/biomedicines12020297; URL: https://doi.org/10.3390/biomedicines12020297) (parvaresh2024unravelingthepotential pages 13-14, parvaresh2024unravelingthepotential pages 11-13).

Cellular programs affected - Proliferation and survival: constitutive ALK signaling upregulates pro-survival programs via STAT3 (BCL2 family, survivin) and PI3K–AKT, while MAPK promotes mitogenic transcription (parvaresh2024unravelingthepotential pages 11-13, parvaresh2024unravelingthepotential pages 9-11). - EMT, migration, invasion: EMT is linked to specific resistance states; for example, “The EML4‑ALK G1202R on-target mutation induces EMT…increasing migration/invasion via STAT3/Slug,” and MMP9-mediated ALK cleavage can enhance motility via β-catenin nuclear effects (Biomedicines 2024) (parvaresh2024unravelingthepotential pages 13-14, parvaresh2024unravelingthepotential pages 9-11). - Chromatin/transcriptional remodeling and plasticity: YAP/TAZ programs (with AXL/EGFR/TGFBR2 upregulation) and lineage plasticity are implicated in bypass resistance and histologic transformation (jimenez2025unravelingtherapeuticstrategies pages 42-46, parvaresh2024unravelingthepotential pages 13-14).

Tumor microenvironment (TME) and immunobiology ALK+ NSCLC generally exhibits an immunosuppressive TIME with relatively low effective CD8+ T-cell activity and enrichment of suppressive subsets (Tregs and/or M2 macrophages), contributing to poor response to PD-1/PD-L1 blockade; TKI initiation can transiently increase CD8+ T cells, but longer-term treatment fosters immunosuppressive remodeling (Frontiers in Immunology 2025; JITC 2024) (lucia2025nonsmallcelllung pages 2-3, parvaresh2024unravelingthepotential pages 13-14). Clinically relevant correlates include low-to-variable PD-L1 expression and typically low tumor mutational burden (TMB), aligning with reduced ICI efficacy; emphasis is shifting to alternative immunomodulatory approaches (adoptive cells, vaccines) (lucia2025nonsmallcelllung pages 2-3, parvaresh2024unravelingthepotential pages 24-27). Importantly, CNS tropism is frequent at baseline (≈20% present with brain metastases), guiding the use of CNS-penetrant TKIs (jimenez2025unravelingtherapeuticstrategies pages 34-37).

Key molecular players (with ontology references) and co-alterations - Genes/Proteins (HGNC): ALK (driver kinase), EML4 (fusion partner), TP53 (~30% co-altered, associated with inferior TKI outcomes), MET (amplification as bypass), EGFR (ligand-driven activation as bypass), CDKN2A/B (co-deletions), NF2 (loss → mTOR activation), KRAS (copy-number gains/reactivation of MAPK), PTPN11/SHP2 (RAS node dependency), SRC (adaptive resistance), STAT3, MYC, YAP1/WWTR1 (TAZ), AXL, TGFBR2, SMYD2, CDK9, MMP9 (testa2024alkrearrangedlungadenocarcinoma pages 1-2, jimenez2025unravelingtherapeuticstrategies pages 34-37, jimenez2025unravelingtherapeuticstrategies pages 42-46, parvaresh2024unravelingthepotential pages 13-14). - Chemical entities (CHEBI): first-/second-/third-generation ALK TKIs (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib) and next-wave inhibitors under development (e.g., 4th-generation concepts NVL‑655, TPX‑0131), and pathway co-inhibitors (EGFR, MEK, PARP) (testa2024alkrearrangedlungadenocarcinoma pages 1-2, parvaresh2024unravelingthepotential pages 24-27, parvaresh2024unravelingthepotential pages 13-14). - Cell types (CL): CD8+ T cells (often functionally constrained), regulatory T cells (Tregs), and M2 macrophages (immunosuppressive) (lucia2025nonsmallcelllung pages 2-3, parvaresh2024unravelingthepotential pages 13-14). - Anatomical locations (UBERON): lung alveolus (primary) and brain parenchyma (frequent metastasis) (testa2024alkrearrangedlungadenocarcinoma pages 1-2, jimenez2025unravelingtherapeuticstrategies pages 34-37).

Embedded ontology mapping table | Category | Item (standardized term) | Ontology | Identifier | Role in disease (1-2 lines) | Key evidence (DOI/URL) | Year | |---|---|---|---:|---|---|---:| | Gene / Protein | ALK | HGNC | HGNC:ALK | Oncogenic fusion kinase driving constitutive RTK signaling (growth/survival). Primary target of ALK-TKIs. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | EML4 | HGNC | HGNC:EML4 | Fusion partner that provides oligomerization domains; variant structure (V1/V2/V3) alters localization/stability and influences oncogenicity and resistance. | https://doi.org/10.1177/03008916231202149 (testa2024alkrearrangedlungadenocarcinoma pages 1-2), https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | TP53 | HGNC | HGNC:TP53 | Frequent co-mutation; associated with worse TKI responses and shorter PFS/OS in ALK+ NSCLC. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | MET | HGNC | HGNC:MET | Bypass driver via amplification/reactivation causing ALK-independent resistance; targetable in combo strategies. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | EGFR | HGNC | HGNC:EGFR | Can act as bypass pathway (ligand-driven phosphorylation) in ALK-TKI resistance; rationale for combination EGFR+ALK in select cases. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | CDKN2A | HGNC | HGNC:CDKN2A | Tumor suppressor co-altered in some ALK+ tumors; implicates cell-cycle deregulation and worse prognosis. | https://doi.org/10.1177/03008916231202149 (testa2024alkrearrangedlungadenocarcinoma pages 1-2) | 2024 | | Gene / Protein | CDKN2B | HGNC | HGNC:CDKN2B | Co-deletion with CDKN2A in subsets; contributes to cell-cycle control loss. | https://doi.org/10.1177/03008916231202149 (testa2024alkrearrangedlungadenocarcinoma pages 1-2) | 2024 | | Gene / Protein | NF2 | HGNC | HGNC:NF2 | Loss can activate mTOR signaling and mediate lorlatinib resistance; suggests mTOR-targeted strategies. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | KRAS | HGNC | HGNC:KRAS | Rare co-alteration; RAS/MAPK reactivation via copy-number gain/reactivation can bypass ALK inhibition. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | PTPN11 (SHP2) | HGNC | HGNC:PTPN11 | Functional node upstream of RAS—identified as dependency in bypass resistance; combined SHP2+ALK inhibition under evaluation. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | SRC | HGNC | HGNC:SRC | Src-family kinase implicated in adaptive resistance/tolerance; Src inhibitors show preclinical synergy with ALK-TKIs. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | STAT3 | HGNC | HGNC:STAT3 | Downstream effector of ALK; mediates survival, EMT and resistance phenotypes (combination ALK+STAT3 can restore sensitivity). | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | MYC | HGNC | HGNC:MYC | ALK-driven transcriptional programs can upregulate MYC; MYC suppression sensitizes ALK+ cells to TKIs in preclinical data. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | YAP1 | HGNC | HGNC:YAP1 | YAP-driven transcription links to bypass (AXL/EGFR/TGFBR2) and lineage-plasticity-mediated resistance. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | WWTR1 (TAZ) | HGNC | HGNC:WWTR1 | Hippo-pathway effector (TAZ) cooperating with YAP in remodeling resistance-associated transcriptional programs. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | AXL | HGNC | HGNC:AXL | RTK upregulated via YAP/TAZ; contributes to EMT and bypass signaling. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | TGFBR2 | HGNC | HGNC:TGFBR2 | TGF-β receptor linked to EMT/lineage plasticity and resistance programs. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | SMYD2 | HGNC | HGNC:SMYD2 | Methyltransferase that post-translationally modifies ALK to promote AKT activation; SMYD2 inhibition synergizes with ALK-TKIs preclinically. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | CDK9 | HGNC | HGNC:CDK9 | ALK phosphorylation of CDK9 links to homologous recombination and PARP-inhibitor resistance; rationale for ALK+PARP combinations. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Gene / Protein | MMP9 | HGNC | HGNC:MMP9 | Mediates proteolytic ALK cleavage affecting β-catenin release and motility; implicated in invasion/migration. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Biological Process | MAPK cascade (RAS-RAF-MEK-ERK) | GO | GO:MAPK_cascade | Major mitogenic pathway downstream of ALK; reactivation (KRAS, DUSP6 loss) is common bypass route. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Biological Process | PI3K-AKT-mTOR signaling | GO | GO:PI3K-AKT_mTOR | Promotes survival and anti-apoptosis; NF2 loss → mTOR activation mediates lorlatinib resistance. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Biological Process | JAK-STAT cascade | GO | GO:JAK-STAT | STAT3-driven survival and EMT programs downstream of ALK; contributes to resistance and prosurvival gene expression. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Biological Process | Phospholipase C-activating receptor signaling (PLCγ) | GO | GO:PLC_gamma_pathway | ALK activates PLCγ → PKC/Ca2+ signaling affecting proliferation and cytoskeletal dynamics. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Biological Process | Epithelial–mesenchymal transition (EMT) | GO | GO:EMT | EMT is induced by certain ALK mutations (e.g., G1202R) and correlates with invasion and therapeutic resistance. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Biological Process | Cell proliferation | GO | GO:cell_proliferation | Core oncogenic outcome of ALK signaling via MAPK/PI3K pathways. | https://doi.org/10.1177/03008916231202149 (testa2024alkrearrangedlungadenocarcinoma pages 1-2) | 2024 | | Biological Process | Regulation of apoptosis / survival | GO | GO:apoptosis_regulation | ALK signaling upregulates BCL2/survivin and suppresses pro-apoptotic factors; key determinant of TKI response. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Biological Process | Chromatin remodeling / transcriptional reprogramming | GO | GO:chromatin_remodeling | Drives lineage plasticity, immunophenotype changes and SCLC/mesenchymal transformations on therapy pressure. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Biological Process | Cell migration / invasion | GO | GO:cell_migration_invasion | Downstream of EMT, MMP9 activity and cytoskeletal reorganization promoted by ALK fusions. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Biological Process | Immune suppression in TME | GO | GO:immune_suppression_TME | ALK+ tumors often display immunosuppressive TIME (low CD8, high Tregs/M2), limiting ICI responses. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Cellular Component | Plasma membrane | GO | GO:plasma_membrane | Location of RTK signaling complexes and receptor interactions (bypass RTKs). | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Cellular Component | Cytoplasm | GO | GO:cytoplasm | Subcellular compartment for many ALK fusion signaling events and cytosolic adaptor recruitment. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Cellular Component | Microtubules | GO | GO:microtubule | EML4 contribution to microtubule binding (variant-specific localization, e.g., V3) influencing signaling granules. | https://doi.org/10.1177/03008916231202149 (testa2024alkrearrangedlungadenocarcinoma pages 1-2) | 2024 | | Cellular Component | Membraneless cytoplasmic granules | GO | GO:membraneless_granules | Variant-specific condensates concentrate RAS-MAPK components and modulate signaling strength. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Cellular Component | Nucleus | GO | GO:nucleus | Nuclear translocation of transcriptional effectors (β-catenin, MYC) mediates proliferation/invasion programs. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Cell Type | CD8+ T cell | CL | CL:CD8+_T_cell | Key antitumor effector; typically reduced/inactive in ALK+ TIME but can be transiently increased after TKI. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Cell Type | Regulatory T cell (Treg) | CL | CL:Treg | Enriched in ALK+ TIME in some studies, contributing to immunosuppression. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Cell Type | M2 macrophage | CL | CL:M2_macrophage | Immunosuppressive macrophage phenotype associated with ALK+ brain metastases and resistance milieu. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Cell Type | B cell | CL | CL:B_cell | Reduced/variable B cell infiltration reported; role in ALK+ TIME remains under study. | https://doi.org/10.1177/03008916231202149 (testa2024alkrearrangedlungadenocarcinoma pages 1-2) | 2024 | | Anatomical Location | Lung alveolus (primary) | UBERON | UBERON:lung_alveolus | Primary site of tumorigenesis in lung adenocarcinoma harboring ALK fusions. | https://doi.org/10.1177/03008916231202149 (testa2024alkrearrangedlungadenocarcinoma pages 1-2) | 2024 | | Anatomical Location | Brain parenchyma (metastasis) | UBERON | UBERON:brain_parenchyma | ALK+ NSCLC shows CNS tropism; brain metastases common and influence choice of CNS-penetrant TKIs. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Chemical Entity | Lorlatinib | CHEBI | CHEBI:Lorlatinib | Third-generation, CNS-penetrant ALK-TKI active against many single ALK mutations; resistance via compound mutations/bypass emerges. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Chemical Entity | Alectinib | CHEBI | CHEBI:Alectinib | Second-generation ALK inhibitor with superior CNS control vs crizotinib; frontline option. | https://doi.org/10.1177/03008916231202149 (testa2024alkrearrangedlungadenocarcinoma pages 1-2) | 2024 | | Chemical Entity | Brigatinib | CHEBI | CHEBI:Brigatinib | Second-generation ALK-TKI with CNS activity; part of sequencing strategies. | https://doi.org/10.1177/03008916231202149 (testa2024alkrearrangedlungadenocarcinoma pages 1-2) | 2024 | | Chemical Entity | Ceritinib | CHEBI | CHEBI:Ceritinib | Second-generation ALK inhibitor active post-crizotinib; resistance patterns include ALK mutations. | https://doi.org/10.1177/03008916231202149 (testa2024alkrearrangedlungadenocarcinoma pages 1-2) | 2024 | | Chemical Entity | Crizotinib | CHEBI | CHEBI:Crizotinib | First-generation ALK/MET/ROS1 inhibitor; foundational TKI with earlier resistance patterns. | https://doi.org/10.1177/03008916231202149 (testa2024alkrearrangedlungadenocarcinoma pages 1-2) | 2024 | | Chemical Entity | NVL-655 | CHEBI | CHEBI:NVL-655 | Fourth-generation ALK inhibitor in development with activity against lorlatinib-resistant compound mutations (preclinical/early clinical data). | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Chemical Entity | TPX-0131 | CHEBI | CHEBI:TPX-0131 | 4th-gen ALK inhibitor designed to overcome compound mutations; development-stage therapeutic strategy. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Chemical Entity | PARP inhibitors | CHEBI | CHEBI:PARP_inhibitor | Combination rationale with ALK inhibitors due to ALK→CDK9→HR axis; preclinical synergy reported. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Chemical Entity | MEK inhibitors | CHEBI | CHEBI:MEK_inhibitor | Target downstream MAPK reactivation in bypass resistance; ALK+MEK combos show preclinical promise. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 | | Chemical Entity | EGFR inhibitors | CHEBI | CHEBI:EGFR_inhibitor | Employed to target EGFR-driven bypass activation in select ALK-TKI resistant contexts. | https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14) | 2024 |

Table: A compact ontology-mapped table linking genes, processes, compartments, cell types, locations and key drugs to their roles in ALK‑rearranged NSCLC, with evidence citations to recent reviews (2024). This aids database annotation and mechanistic curation.

GO-aligned biological processes and cellular components - Disrupted processes (GO): MAPK cascade; PI3K–AKT–mTOR signaling; JAK–STAT signaling; phospholipase C–activating signaling; epithelial–mesenchymal transition; regulation of apoptosis/survival; chromatin remodeling/transcriptional reprogramming; cell migration/invasion; immune suppression in TME. Evidence: synthesis from 2024–2025 mechanistic reviews indicating ALK→STAT3/ERK/AKT/PLCγ axes, EMT with G1202R, and TME suppression (jimenez2025unravelingtherapeuticstrategies pages 28-31, parvaresh2024unravelingthepotential pages 9-11, parvaresh2024unravelingthepotential pages 13-14, parvaresh2024unravelingthepotential pages 11-13). - Cellular components (GO): plasma membrane (RTK complexes/bypass RTKs), cytoplasm (signalosomes), microtubules (variant V3 localization), membraneless cytoplasmic granules (condensates concentrating RAS-MAPK components), and nucleus (transcriptional effectors) (jimenez2025unravelingtherapeuticstrategies pages 31-34, parvaresh2024unravelingthepotential pages 9-11).

Disease progression: sequence of events 1) Initiation: ALK fusion formation (most commonly EML4‑ALK), generating a constitutively active ALK kinase chimera through EML4-mediated oligomerization and autophosphorylation (testa2024alkrearrangedlungadenocarcinoma pages 1-2, jimenez2025unravelingtherapeuticstrategies pages 31-34). 2) Early tumorigenesis: Oncogene addiction to ALK with activation of MAPK/PI3K/STAT3/PLCγ signaling, promoting proliferation, survival, and invasion programs (jimenez2025unravelingtherapeuticstrategies pages 28-31, parvaresh2024unravelingthepotential pages 11-13). 3) Clinical presentation: Often in younger, light/never-smokers; significant CNS tropism at diagnosis; relative immunologically “cold” TME (jimenez2025unravelingtherapeuticstrategies pages 34-37, lucia2025nonsmallcelllung pages 2-3). 4) Treatment phase: High sensitivity to ALK TKIs; CNS-penetrant agents (alectinib, brigatinib, lorlatinib) improve brain control versus crizotinib (testa2024alkrearrangedlungadenocarcinoma pages 1-2, bearz2025eml4alkupdateon pages 4-6). 5) Acquired resistance evolution: On-target ALK kinase-domain mutations (e.g., L1196M, I1171X, F1174X, G1269A, G1202R), frequently “compound” mutations after lorlatinib; ALK-independent bypass (MET amplification; EGFR/HER signaling; RAS/MAPK reactivation through SHP2, KRAS CN gains, DUSP6 loss; SRC activation); phenotypic plasticity including EMT and histologic transformation (squamous or small-cell) (jimenez2025unravelingtherapeuticstrategies pages 42-46, parvaresh2024unravelingthepotential pages 13-14). 6) Late-stage dynamics: Progressive TME immunosuppression during prolonged TKI exposure; potential opportunities for immunomodulatory strategies beyond PD-1/PD-L1 monotherapy (lucia2025nonsmallcelllung pages 2-3, parvaresh2024unravelingthepotential pages 24-27).

Phenotypic manifestations and clinical correlates - Key clinical phenotypes: Lung adenocarcinoma with high likelihood of brain metastases at baseline and over the disease course; strong initial TKI responses with eventual resistance; generally limited benefit from standalone immune checkpoint blockade (jimenez2025unravelingtherapeuticstrategies pages 34-37, lucia2025nonsmallcelllung pages 2-3). - Variant-specific risk: V3 is frequently associated with more aggressive clinical behavior and enrichment of G1202R upon resistance; V1 more often selects for L1196M/F1174C (2025 synthesis drawing on earlier variant literature) (jimenez2025unravelingtherapeuticstrategies pages 42-46, jimenez2025unravelingtherapeuticstrategies pages 31-34). - PD-L1/TMB: Typically low TMB and variable PD-L1; immunosuppressive TIME features (Tregs, M2 macrophages) likely contribute to modest ICI efficacy (lucia2025nonsmallcelllung pages 2-3, parvaresh2024unravelingthepotential pages 13-14).

Recent developments and latest research (prioritized 2023–2024) - Consolidated fusion/variant biology and clinical implications updated through 2024 Tumori review (Testa et al.), including major EML4‑ALK variants and therapeutic framing (Sep 2024; https://doi.org/10.1177/03008916231202149) (testa2024alkrearrangedlungadenocarcinoma pages 1-2). - Mechanistic advances detailing ALK-driven pathways, EMT linkage to G1202R, ALK methylation by SMYD2→AKT activation, and multi-target combination strategies (ALK+MEK; ALK+STAT3; ALK+EGFR; ALK+PARP) (Biomedicines, Jan 2024; https://doi.org/10.3390/biomedicines12020297) (parvaresh2024unravelingthepotential pages 13-14, parvaresh2024unravelingthepotential pages 11-13). - Resistance in the second-/third-generation era: reviews and syntheses underscore the prevalence of ALK-independent resistance without kinase-domain mutations after earlier TKIs (~50–70% post-crizotinib; ~50% post-2G), with MET, EGFR, YAP/TAZ, SRC, SHP2/RAS reactivation and NF2/mTOR signaling as recurrent routes; after lorlatinib, complex on-target compound mutations and bypass co-emerge (2025 synthesis of 2023–2024 observations) (jimenez2025unravelingtherapeuticstrategies pages 42-46). - Tumor microenvironment dynamics under TKIs: short-term TKI can transiently enhance antitumor immunity (CD8+), whereas long-term therapy fosters an immunosuppressive TME—guiding timing and design of combinations (JITC, Jun 2024; DOI:10.1136/jitc-2024-009165) (lucia2025nonsmallcelllung pages 2-3, parvaresh2024unravelingthepotential pages 13-14). - Brain metastasis management: later-generation TKIs (alectinib, brigatinib, lorlatinib) provide superior CNS control relative to crizotinib and inform frontline selection (IJMS update table, 2025; but CNS emphasis consistent with 2024 landscape) (bearz2025eml4alkupdateon pages 4-6, testa2024alkrearrangedlungadenocarcinoma pages 1-2).

Current applications and implementations - Frontline therapy: alectinib, brigatinib, and lorlatinib as CNS-active first-line options; selection guided by comorbidities, CNS disease, and anticipated resistance patterns (testa2024alkrearrangedlungadenocarcinoma pages 1-2, bearz2025eml4alkupdateon pages 4-6). - Resistance-guided therapy: molecular re-biopsy/ctDNA to define on-target mutations versus bypass mechanisms; lorlatinib for many single mutations; development of 4th‑generation ALK inhibitors (e.g., NVL‑655, TPX‑0131) and rational combinations (ALK+SHP2/MEK/mTOR/EGFR; ALK+PARP) for compound and bypass resistance (parvaresh2024unravelingthepotential pages 24-27, jimenez2025unravelingtherapeuticstrategies pages 42-46, parvaresh2024unravelingthepotential pages 13-14). - Immunotherapy strategies: limited efficacy of PD-1/PD-L1 monotherapy; exploration of ALK vaccines and adoptive cellular strategies to overcome immunosuppression (parvaresh2024unravelingthepotential pages 24-27, lucia2025nonsmallcelllung pages 2-3).

Expert opinions and authoritative analyses - Testa et al. (Tumori 2024) conclude that while “ALK-TKIs have improved outcomes…resistance mechanisms greatly limit durability,” and new strategies aim for long-term remission, underscoring the need for variant-aware and resistance-agnostic approaches (testa2024alkrearrangedlungadenocarcinoma pages 1-2). - Cross-review synthesis highlights that a substantial fraction of progression events are ALK-independent, elevating the importance of bypass-pathway cotargeting (SHP2/RAS-MAPK, MET, EGFR) and vigilance for lineage transformation (jimenez2025unravelingtherapeuticstrategies pages 42-46). - Immunology-focused analyses emphasize immunosuppressive TME characteristics in ALK+ disease and the dynamic remodeling under TKIs, supporting time-sensitive combinations rather than ICI monotherapy (lucia2025nonsmallcelllung pages 2-3, parvaresh2024unravelingthepotential pages 24-27).

Statistics and recent data points - Prevalence: ALK fusions approximately 2–8% of LUAD (often cited 2–3%) (Sep 2024) (testa2024alkrearrangedlungadenocarcinoma pages 1-2). - Variant distribution (ranges vary by cohort): V1 ~33–43%, V3 ~29–42% (2025 synthesis of variant literature; consistent with historical patterns) (jimenez2025unravelingtherapeuticstrategies pages 31-34, jimenez2025unravelingtherapeuticstrategies pages 34-37). - Co-alterations: TP53 is the most frequent (~30% of EML4‑ALK) and is generally associated with worse TKI outcomes (2025 synthesis; 2024 updates) (jimenez2025unravelingtherapeuticstrategies pages 34-37). - Resistance spectra: A large fraction of resistance after crizotinib and second-generation TKIs lacks detectable ALK kinase-domain mutations (~50–70% and ~50%, respectively), indicating prominent bypass resistance; lorlatinib resistance frequently involves compound ALK mutations plus bypass alterations (2025 synthesis summarizing 2023–2024 observations) (jimenez2025unravelingtherapeuticstrategies pages 42-46). - CNS involvement: approximately 20% present with brain metastases at diagnosis (jimenez2025unravelingtherapeuticstrategies pages 34-37).

Evidence items (PMIDs/DOIs/URLs, publication dates) - Testa U, Castelli G, Pelosi E. Alk‑rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting. Tumori. Sep 2024. DOI:10.1177/03008916231202149. URL: https://doi.org/10.1177/03008916231202149 (testa2024alkrearrangedlungadenocarcinoma pages 1-2). - Parvaresh H, et al. Unraveling the Potential of ALK-Targeted Therapies in NSCLC. Biomedicines. Jan 2024. DOI:10.3390/biomedicines12020297. URL: https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14, parvaresh2024unravelingthepotential pages 11-13, parvaresh2024unravelingthepotential pages 9-11). - De Lucia A, et al. NSCLC and the tumor microenvironment. Frontiers in Immunology. Feb 2025. DOI:10.3389/fimmu.2025.1515748. URL: https://doi.org/10.3389/fimmu.2025.1515748 (lucia2025nonsmallcelllung pages 2-3). - Variant and resistance synthesis (EML4‑ALK V1/V3; on-target vs bypass; SHP2/MAPK/NF2‑mTOR; transformation). 2025 synthesis (bioRxiv-based and review integrations) (jimenez2025unravelingtherapeuticstrategies pages 34-37, jimenez2025unravelingtherapeuticstrategies pages 42-46, jimenez2025unravelingtherapeuticstrategies pages 28-31, jimenez2025unravelingtherapeuticstrategies pages 31-34). - Clinical CNS control and first-line comparisons including post‑crizotinib sequences (summary table). IJMS 2025 update; aligns with 2024 practice trends (bearz2025eml4alkupdateon pages 4-6).

Ontology-grounded annotations - Genes/Proteins (HGNC): ALK (HGNC:ALK); EML4 (HGNC:EML4); TP53 (HGNC:TP53); MET (HGNC:MET); EGFR (HGNC:EGFR); CDKN2A (HGNC:CDKN2A); CDKN2B (HGNC:CDKN2B); NF2 (HGNC:NF2); KRAS (HGNC:KRAS); PTPN11/SHP2 (HGNC:PTPN11); SRC (HGNC:SRC); STAT3 (HGNC:STAT3); MYC (HGNC:MYC); YAP1 (HGNC:YAP1); WWTR1/TAZ (HGNC:WWTR1); AXL (HGNC:AXL); TGFBR2 (HGNC:TGFBR2); SMYD2 (HGNC:SMYD2); CDK9 (HGNC:CDK9); MMP9 (HGNC:MMP9). Roles summarized above (testa2024alkrearrangedlungadenocarcinoma pages 1-2, parvaresh2024unravelingthepotential pages 13-14, jimenez2025unravelingtherapeuticstrategies pages 42-46). - Biological Processes (GO): MAPK cascade; PI3K–AKT–mTOR signaling; JAK–STAT cascade; PLCγ-activating signaling; EMT; proliferation; apoptosis regulation; chromatin remodeling; migration/invasion; immune suppression in TME (jimenez2025unravelingtherapeuticstrategies pages 28-31, parvaresh2024unravelingthepotential pages 9-11, parvaresh2024unravelingthepotential pages 13-14). - Cellular Components (GO): plasma membrane; cytoplasm; microtubules; membraneless cytoplasmic granules; nucleus (jimenez2025unravelingtherapeuticstrategies pages 31-34, parvaresh2024unravelingthepotential pages 9-11). - Cell Types (CL): CD8+ T cell; regulatory T cell; M2 macrophage; B cell (lucia2025nonsmallcelllung pages 2-3, parvaresh2024unravelingthepotential pages 13-14, testa2024alkrearrangedlungadenocarcinoma pages 1-2). - Anatomical Locations (UBERON): lung alveolus; brain parenchyma (testa2024alkrearrangedlungadenocarcinoma pages 1-2, jimenez2025unravelingtherapeuticstrategies pages 34-37). - Chemical Entities (CHEBI): crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, NVL‑655, TPX‑0131, EGFR inhibitors, MEK inhibitors, PARP inhibitors (testa2024alkrearrangedlungadenocarcinoma pages 1-2, parvaresh2024unravelingthepotential pages 24-27, bearz2025eml4alkupdateon pages 4-6, parvaresh2024unravelingthepotential pages 13-14).

Direct supporting quotes - “EML4‑ALK arises from different EML4 breakpoints producing main variants—variant 1 (EML4 exon13::ALK exon20), variant 2 … and variant 3 (EML4 exon6a/6b::ALK exon20)” (Testa 2024) (testa2024alkrearrangedlungadenocarcinoma pages 1-2). - “The EML4‑ALK G1202R on-target mutation induces EMT, increasing migration/invasion via STAT3 and Slug; combined ALK+STAT3 inhibition can restore TKI sensitivity” (Biomedicines 2024) (parvaresh2024unravelingthepotential pages 13-14). - “A large fraction of patients progressing on crizotinib or second-generation inhibitors lack detectable kinase-domain point mutations…indicating widespread ALK-independent resistance” (2025 synthesis summarizing 2023–2024 observations) (jimenez2025unravelingtherapeuticstrategies pages 42-46).

Limitations Some 2025 syntheses are used to summarize 2023–2024 findings where accessible; primary 2024 peer‑reviewed sources (Tumori; Biomedicines) support core mechanisms, while 2025 immunology and mechanistic syntheses are used for TME and resistance contextualization. Where possible, URLs and DOIs are provided.

References (with URLs/dates) mapped to context IDs - Testa U, Castelli G, Pelosi E. Tumori. Sep 2024. https://doi.org/10.1177/03008916231202149 (testa2024alkrearrangedlungadenocarcinoma pages 1-2) - Parvaresh H, et al. Biomedicines. Jan 2024. https://doi.org/10.3390/biomedicines12020297 (parvaresh2024unravelingthepotential pages 13-14, parvaresh2024unravelingthepotential pages 11-13, parvaresh2024unravelingthepotential pages 9-11) - De Lucia A, et al. Frontiers in Immunology. Feb 2025. https://doi.org/10.3389/fimmu.2025.1515748 (lucia2025nonsmallcelllung pages 2-3) - Diaz-Jimenez A. 2025 synthesis: variant distribution; resistance spectrum and bypass pathways including SHP2/RAS-MAPK, MET, EGFR, NF2/mTOR; lineage transformation (jimenez2025unravelingtherapeuticstrategies pages 34-37, jimenez2025unravelingtherapeuticstrategies pages 42-46, jimenez2025unravelingtherapeuticstrategies pages 28-31, jimenez2025unravelingtherapeuticstrategies pages 31-34) - Bearz A, et al. IJMS update table (first-line/CNS control; sequencing context). Jan 2025. https://doi.org/10.3390/ijms26010308 (bearz2025eml4alkupdateon pages 4-6)

Citations for claims in text are provided at the end of the relevant sentences above using context IDs.

References

  1. (testa2024alkrearrangedlungadenocarcinoma pages 1-2): Ugo Testa, Germana Castelli, and Elvira Pelosi. Alk-rearranged lung adenocarcinoma: from molecular genetics to therapeutic targeting. Tumori, 110:88-95, Sep 2024. URL: https://doi.org/10.1177/03008916231202149, doi:10.1177/03008916231202149. This article has 17 citations and is from a peer-reviewed journal.

  2. (parvaresh2024unravelingthepotential pages 24-27): Hannaneh Parvaresh, Ghazaal Roozitalab, Fatemeh Golandam, Payam Behzadi, and Parham Jabbarzadeh Kaboli. Unraveling the potential of alk-targeted therapies in non-small cell lung cancer: comprehensive insights and future directions. Biomedicines, 12:297, Jan 2024. URL: https://doi.org/10.3390/biomedicines12020297, doi:10.3390/biomedicines12020297. This article has 42 citations and is from a poor quality or predatory journal.

  3. (lucia2025nonsmallcelllung pages 2-3): Anna De Lucia, Lucia Mazzotti, Anna Gaimari, Matteo Zurlo, Roberta Maltoni, Claudio Cerchione, Sara Bravaccini, Angelo Delmonte, Lucio Crinò, Patricia Borges de Souza, Luigi Pasini, Fabio Nicolini, Fabrizio Bianchi, Manel Juan, Hugo Calderon, Chiara Magnoni, Luca Gazzola, Paola Ulivi, and Massimiliano Mazza. Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy. Frontiers in Immunology, Feb 2025. URL: https://doi.org/10.3389/fimmu.2025.1515748, doi:10.3389/fimmu.2025.1515748. This article has 10 citations and is from a peer-reviewed journal.

  4. (jimenez2025unravelingtherapeuticstrategies pages 31-34): A Diaz Jimenez. Unraveling therapeutic strategies and tumor suppressor functions in eml4-alk-driven lung tumorigenesis. Unknown journal, 2025.

  5. (jimenez2025unravelingtherapeuticstrategies pages 28-31): A Diaz Jimenez. Unraveling therapeutic strategies and tumor suppressor functions in eml4-alk-driven lung tumorigenesis. Unknown journal, 2025.

  6. (parvaresh2024unravelingthepotential pages 9-11): Hannaneh Parvaresh, Ghazaal Roozitalab, Fatemeh Golandam, Payam Behzadi, and Parham Jabbarzadeh Kaboli. Unraveling the potential of alk-targeted therapies in non-small cell lung cancer: comprehensive insights and future directions. Biomedicines, 12:297, Jan 2024. URL: https://doi.org/10.3390/biomedicines12020297, doi:10.3390/biomedicines12020297. This article has 42 citations and is from a poor quality or predatory journal.

  7. (parvaresh2024unravelingthepotential pages 13-14): Hannaneh Parvaresh, Ghazaal Roozitalab, Fatemeh Golandam, Payam Behzadi, and Parham Jabbarzadeh Kaboli. Unraveling the potential of alk-targeted therapies in non-small cell lung cancer: comprehensive insights and future directions. Biomedicines, 12:297, Jan 2024. URL: https://doi.org/10.3390/biomedicines12020297, doi:10.3390/biomedicines12020297. This article has 42 citations and is from a poor quality or predatory journal.

  8. (parvaresh2024unravelingthepotential pages 11-13): Hannaneh Parvaresh, Ghazaal Roozitalab, Fatemeh Golandam, Payam Behzadi, and Parham Jabbarzadeh Kaboli. Unraveling the potential of alk-targeted therapies in non-small cell lung cancer: comprehensive insights and future directions. Biomedicines, 12:297, Jan 2024. URL: https://doi.org/10.3390/biomedicines12020297, doi:10.3390/biomedicines12020297. This article has 42 citations and is from a poor quality or predatory journal.

  9. (jimenez2025unravelingtherapeuticstrategies pages 42-46): A Diaz Jimenez. Unraveling therapeutic strategies and tumor suppressor functions in eml4-alk-driven lung tumorigenesis. Unknown journal, 2025.

  10. (jimenez2025unravelingtherapeuticstrategies pages 34-37): A Diaz Jimenez. Unraveling therapeutic strategies and tumor suppressor functions in eml4-alk-driven lung tumorigenesis. Unknown journal, 2025.

  11. (bearz2025eml4alkupdateon pages 4-6): Alessandra Bearz, Elisa Bertoli, Brigida Stanzione, Elisa De Carlo, Alessandro Del Conte, Martina Bortolot, Sara Torresan, Eleonora Berto, Valentina Da Ros, Giulia Maria Pelin, Kelly Fassetta, Silvia Rossetto, and Michele Spina. Eml4-alk: update on alk inhibitors. International Journal of Molecular Sciences, 26:308, Jan 2025. URL: https://doi.org/10.3390/ijms26010308, doi:10.3390/ijms26010308. This article has 7 citations and is from a poor quality or predatory journal.

OpenScientist ▸
1. Disease Information
openscientist-autonomous 69 citations 2026-05-06T02:08:06.407062

1. Disease Information

Overview

ALK-rearranged NSCLC is a genomically defined subtype of non-small cell lung cancer characterized by somatic rearrangements of the ALK gene that produce constitutively active fusion proteins, most commonly EML4-ALK. First identified in 2007 by Soda et al., the EML4-ALK fusion gene results from "a small inversion within chromosome 2p [that] results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells" (PMID: 17625570). This landmark discovery established EML4-ALK as a transforming oncogene, as mouse 3T3 fibroblasts expressing the fusion generated transformed foci in culture and subcutaneous tumors in nude mice.

ALK-rearranged NSCLC is recognized as an "oncogene-addicted cancer with peculiar clinical characteristics" (PMID: 39160676), making it exquisitely sensitive to ALK-targeted therapy but largely resistant to immune checkpoint inhibitors.

Key Identifiers

Database Identifier Term
NCIT C215346 ALK-Positive Lung Non-Small Cell Carcinoma
MONDO 0005233 Non-small cell lung carcinoma
MONDO 0005061 Lung adenocarcinoma
SNOMED CT 254637007 Non-small cell lung cancer
ICD-10 C34 Malignant neoplasm of bronchus and lung
MeSH D002289 Carcinoma, Non-Small-Cell Lung
KEGG hsa05223 Non-small cell lung cancer pathway
OMIM 164731 ALK gene

Common Synonyms

  • ALK-positive NSCLC / ALK+ NSCLC
  • ALK-rearranged lung cancer
  • EML4-ALK fusion lung cancer
  • ALK-translocated NSCLC
  • ALK fusion-positive lung adenocarcinoma

Information Sources

This characterization is derived from aggregated disease-level resources including clinical trial data (CROWN, ALEX, ALINA, ALTA-1L), real-world cohort studies, systematic reviews, and molecular biology research, rather than individual patient EHR data.

2. Etiology

Disease Causal Factors

The primary cause is a somatic chromosomal rearrangement — specifically, a paracentric inversion within chromosome 2p — that fuses the N-terminal portion of EML4 (chr2p21) with the kinase domain of ALK (chr2p23). This creates a constitutively active fusion tyrosine kinase. The rearrangement is exclusively somatic (not inherited) and represents a classic oncogenic driver mutation.

Gene Information: - ALK (Anaplastic Lymphoma Kinase): HGNC:427, Ensembl:ENSG00000171094, UniProt:Q9UM73, NCBI Gene:238, chr2p23.2-p23.1 - EML4 (Echinoderm Microtubule Associated Protein Like 4): HGNC:1316, Ensembl:ENSG00000143924, chr2p21

Risk Factors

Genetic Risk Factors

  • Somatic EML4-ALK fusion: The defining oncogenic event; detected in 5–7% of adenocarcinomas (PMID: 22129856)
  • TP53 co-mutations: Present in ~20% of ALK+ cases, associated with dramatically worse outcomes (V3+TP53: HR=9.1 for death, p=0.02) (PMID: 30255938)
  • EML4-ALK variant type: V3 confers worse prognosis than V1 (HR=1.53, 95%CI: 1.17–1.99, p=0.002) (PMID: 41959926)
  • Intra-tumoral fusion isoform heterogeneity: 47.1% harbor multiple isoforms; associated with worse PFS (HR=2.45) and OS (HR=3.74) (PMID: 34626839)
  • No known germline susceptibility loci specifically for ALK rearrangement

Environmental Risk Factors

ALK-rearranged NSCLC predominantly occurs in never-smokers, distinguishing it from smoking-associated NSCLC. Environmental risk factors for lung cancer in never-smokers (LCINS) include:

  • Radon exposure: OR=1.73 (95%CI: 1.27–2.35) for exposure >=200 Bq/m3 (PMID: 30903971)
  • Air pollution: Ambient and indoor air pollution
  • Secondhand smoke: Passive tobacco smoke exposure
  • Occupational exposures: Various industrial carcinogens
  • Infectious agents: Mycobacterium tuberculosis and HPV have been implicated (PMID: 32062313)
  • Cooking fume exposure: Particularly in Asian populations without adequate ventilation

LCINS "constitutes a growing global health challenge, accounting for 10%–25% of lung cancer cases and ranking as the fifth leading cause of cancer-related death worldwide" (PMID: 41591250).

Demographic Enrichment

ALK rearrangement is significantly enriched in: - Adenocarcinomas (6.8%, p<0.001) - Younger patients (p<0.0007) - Women (7.6%, p<0.001) - Never-smokers (8.9%, p<0.001)

(PMID: 22129856)

Protective Factors

  • No specific genetic protective variants for ALK rearrangement have been identified
  • General lung cancer risk reduction through radon mitigation, avoidance of secondhand smoke, and cooking ventilation is relevant given the never-smoker predominance

Gene-Environment Interactions

Radon exposure has been linked to genetic alterations in ABL2, SMARCA4, PIK3R2, and MAPK1 in never-smoker lung cancers (PMID: 30008631). Whether these interact specifically with ALK rearrangement susceptibility remains unknown.

3. Phenotypes

Clinical Symptoms and Signs

Phenotype HPO Term Type Frequency Severity Progression
Lung neoplasm HP:0100526 Clinical sign 100% Variable Progressive
Cough HP:0012735 Symptom 50–75% Mild to severe Progressive
Dyspnea HP:0002094 Symptom 30–60% Moderate to severe Progressive
Hemoptysis HP:0002105 Symptom 20–30% Variable Episodic
Weight loss HP:0001824 Symptom 30–50% Moderate Progressive
Chest pain HP:0100749 Symptom 20–40% Variable Progressive
Pleural effusion HP:0002202 Clinical sign 20–35% Moderate to severe Progressive
Brain metastases HP:0100634 Clinical sign 29% at diagnosis Severe Progressive
Fatigue HP:0012378 Symptom 40–60% Moderate Progressive

Age of Onset

  • Typical onset: Adult, median age 55–60 years
  • Young patients (<50 years): 14.2% of ALK+ cases, median age 44 years (PMID: 31894386)
  • Onset pattern: Insidious; many patients diagnosed at advanced stage

Distinctive Features

ALK+ NSCLC patients are younger than typical NSCLC: "The median age was 55 years (IQR, 45–67); 86% had Eastern Cooperative Oncology Group <=1, 58% were women, and 57% were nonsmokers. Brain metastases were present at diagnosis in 29%" (PMID: 41043103).

Quality of Life Impact

Brain metastases (cumulative incidence >50%) significantly impair quality of life, causing neurological symptoms, cognitive decline, and functional dependence. ALK TKI treatment substantially improves QoL: the Cochrane analysis demonstrated "ALK inhibitors result in a large increase in the HRQoL measure, time to deterioration (HR 0.52, 95% CI: 0.44 to 0.60)" compared to chemotherapy (PMID: 34994987).

4. Genetic/Molecular Information

Causal Genes

ALK (Anaplastic Lymphoma Kinase) - HGNC: 427 - OMIM: 105590 (gene), 164731 (ALK) - Ensembl: ENSG00000171094 - UniProt: Q9UM73 - Chromosomal location: chr2:29,192,774–29,921,586 (GRCh38) - Normal function: Neuronal receptor tyrosine kinase "essentially and transiently expressed in specific regions of the CNS and PNS, playing important roles in genesis and differentiation of the nervous system" (PMID: 40813394)

EML4 (Echinoderm Microtubule Associated Protein Like 4) - HGNC: 1316 - Ensembl: ENSG00000143924 - Chromosomal location: chr2:42,169,330–42,332,548 (GRCh38)

Pathogenic Variants

Fusion Variants

The EML4-ALK fusion occurs through a paracentric inversion on chromosome 2p with multiple breakpoints in EML4 producing distinct variants:

Variant EML4 Exon–ALK Exon Frequency Clinical Significance
V1 (E13;A20) Exon 13–Exon 20 ~35% Better prognosis, HSP90-dependent
V2 (E20;A20) Exon 20–Exon 20 ~10% Intermediate
V3a/b (E6;A20) Exon 6–Exon 20 ~35–45% Worse prognosis, more resistance

V3 biological basis: "The presence of a partial, probably misfolded beta-propeller domain in variant 1 confers solid-like properties to the compartments it forms, greater dependence on Hsp90 for protein stability and higher cell sensitivity to ALK tyrosine kinase inhibitors (TKIs)" (PMID: 37149843).

Resistance Mutations (Somatic, Acquired)

Mutation Type Resistance Pattern
L1196M Gatekeeper Crizotinib-resistant
G1202R Solvent front Pan-resistant to 1st/2nd gen TKIs
G1269A ATP-binding Crizotinib-resistant
I1171T/N/S Kinase domain Alectinib-resistant
V1180L Kinase domain Alectinib-resistant
L1256F Kinase domain Lorlatinib-resistant
Compound mutations Multiple Resistant to all single-agent TKIs

Non-EML4 Fusion Partners

Rare ALK fusion partners include KIF5B-ALK, TFG-ALK, TNIP2-ALK (PMID: 31521978), CHRNA7-ALK, TACR1-ALK, HIP1-ALK, DYSF-ALK, ITGAV-ALK (PMID: 31894386), and CSNK1G3-ALK (PMID: 40783309).

Chromosomal Abnormalities

The defining abnormality is inv(2)(p21p23), a small paracentric inversion on chromosome 2p. This is cytogenetically cryptic (not visible on standard karyotype) and requires FISH, IHC, or NGS for detection. Alternative rearrangement patterns include isolated 5' ALK deletion detected by FISH (PMID: 26536196).

Epigenetic Information

Resistance to ALK TKIs involves epigenetic changes including EMT induction via STAT3/Slug pathway (PMID: 35085771), SIRT1 silencing affecting AMPK/mTOR/S6K signaling (PMID: 39078281), and gradual, multifactorial adaptation through "acquisition of multiple cooperating genetic and epigenetic adaptive changes" (PMID: 32409712).

5. Environmental Information

Environmental Factors

Since ALK+ NSCLC predominantly affects never-smokers, relevant environmental factors include: - Residential radon: The most well-established environmental risk factor for LCINS (OR=1.73 for >=200 Bq/m3) (PMID: 30903971) - Air pollution: Particulate matter (PM2.5) exposure - Occupational exposures: Asbestos, heavy metals, organic solvents - Domestic fuel smoke: Coal and biomass combustion

Lifestyle Factors

  • Smoking: Notably, ALK+ NSCLC is enriched in never-smokers (57–69% across cohorts)
  • Cooking exposure: Cooking without ventilation assessed in TALENT trial as a risk factor (PMID: 38042167)
  • Diet and exercise: No specific associations established; exercise intervention shown beneficial for managing lorlatinib-related weight gain (PMID: 41357598)

Infectious Agents

  • Mycobacterium tuberculosis: History of TB associated with increased LCINS risk (PMID: 32062313)
  • HPV: Implicated in some LCINS studies, though mechanistic links to ALK rearrangement are unestablished

6. Mechanism / Pathophysiology

Molecular Pathways

The EML4-ALK fusion protein constitutively activates multiple oncogenic signaling cascades:

EML4-ALK Fusion Protein (constitutive kinase)
    |
    +---> RAS-MAPK pathway (hsa04010) -> Cell proliferation
    |       +-- ERK -> Jun -> CD73 upregulation -> Immune evasion
    |
    +---> PI3K-AKT pathway (hsa04151) -> Cell survival, anti-apoptosis
    |       +-- mTOR -> Protein synthesis, cell growth
    |
    +---> JAK-STAT pathway (hsa04630) -> Gene transcription
    |       +-- STAT3 -> EMT, invasion (especially G1202R mutants)
    |
    +---> PLCgamma-ERK pathway -> Proliferative signaling

KEGG Pathways: Non-small cell lung cancer (hsa05223), PI3K-Akt signaling (hsa04151), MAPK signaling (hsa04010), JAK-STAT signaling (hsa04630)

Phase-Separated Signaling Foci

A critical mechanistic insight is that "EML4-ALK V1 and V3 proteins form cytoplasmic foci that contain components of the MAPK, PLCgamma and PI3K signalling pathways" (PMID: 34661367). These phase-separated compartments: - Concentrate signaling components for efficient pathway activation - Are dissolved by ALK inhibitors (ceritinib, lorlatinib) - Show variant-specific behavior: V3 re-localizes to microtubules upon inhibitor treatment - Are stabilized by constitutively active ALK mutations even in the presence of inhibitors

HSP90 Chaperone Dependence

"EML4-ALK [was] identified in complex with multiple cellular chaperones including HSP90" (PMID: 20952506). V1 shows greater HSP90 dependence than V3 due to its misfolded beta-propeller domain, explaining differential drug sensitivity.

Immune Evasion Mechanisms

ALK+ NSCLC exhibits an immune-cold phenotype through multiple mechanisms: - Low TMB: "ALK rearrangements were associated with lower TMB and PD-L1+/TMB-H proportions" (PMID: 33655698) - CD73/adenosine pathway: "Upregulation of CD73/adenosine pathway also contributes to the immune-inert microenvironment" regulated by the ERK-Jun pathway downstream of ALK (PMID: 35598361) - Low CD8+ TILs: Poor T-cell infiltration - Multi-omics confirmation: "ALK/RET/ROS1 fusions [are] linked to immune-cold phenotypes with low tumor mutational burden (TMB) and poor T-cell infiltration" (PMID: 41424613)

GO Terms: protein phosphorylation (GO:0006468), MAPK cascade (GO:0000165), cell proliferation (GO:0008283), signal transduction (GO:0007165), apoptotic process (GO:0006915), cell migration (GO:0016477), epithelial-to-mesenchymal transition (GO:0001837)

Resistance Mechanisms

Resistance evolves through multiple parallel pathways:

  1. Secondary ALK mutations: G1202R (solvent front), L1196M (gatekeeper), compound mutations
  2. Bypass signaling activation:
  3. EGFR activation (PMID: 24199682)
  4. ERBB3/AKT pathway: "Dual inhibition of ALK and ERBB receptors or AKT disrupts RAS/MAPK and AKT/PI3K signalling" (PMID: 39695132)
  5. SRC kinase upregulation (PMID: 38521003)
  6. AXL/GAS6 axis from macrophages and MMP11+ fibroblasts (PMID: 39904499)
  7. YAP activation driving EGFR, AXL, CYR61, and TGFbetaR2 (PMID: 31633304)
  8. Phenotypic transformation: EMT via STAT3/Slug pathway in G1202R mutants — "the expression of EML4-ALK G1202R mutation in A549 cells induced an epithelial-mesenchymal transition (EMT) phenotype and significantly increased the migration and invasion abilities" (PMID: 35085771)
  9. Microenvironment adaptation: Cancer-associated fibroblasts (CAFs) conferring resistance (PMID: 41433419)
  10. Temporal evolution: "Evidence for a hybrid scenario involving the gradual, multifactorial adaptation to the inhibitors through acquisition of multiple cooperating genetic and epigenetic adaptive changes" with temporally restricted collateral sensitivities (PMID: 32409712)

Metabolic Changes

ALK inhibition produces rapid metabolic shutdown: 18F-FDG-PET-CT showed "almost complete inhibition of tumor metabolic activity within 24 hours of ALK inhibitor exposure" (PMID: 20952506).

7. Anatomical Structures Affected

Organ Level

Primary organ: Lung (UBERON:0002048) - Predominantly affects the upper and middle lobes - Adenocarcinoma histology in >95% of cases

Secondary organ involvement (metastatic sites): - Brain (UBERON:0000955) — 29% at diagnosis, cumulative incidence >50% - Liver (UBERON:0002107) — common metastatic site - Bone (UBERON:0002481) — skeletal metastases - Pleura (UBERON:0000977) — pleural effusion in 20–35% - Adrenal glands (UBERON:0002369) - Leptomeninges — up to 10% of ALK+ NSCLC cases

Body systems: Respiratory (primary), nervous (CNS metastases), skeletal, hepatic

Tissue and Cell Level

  • Epithelial tissue: Lung adenocarcinoma arising from type II pneumocytes or Clara cells
  • Cell types affected:
  • Type II alveolar epithelial cells (CL:0002063)
  • Epithelial cells of lung (CL:0000082)
  • Bronchial epithelial cells (CL:0002328)

Characteristic Histopathology

ALK+ NSCLC shows distinctive histological features: "Acinar, cribriform, and solid growth patterns, extracellular and intracellular mucin production, and presence of signet-ring-cell element, and psammoma body were significantly more often present in ALK-positive cancer" (PMID: 26095438). Additional features include goblet cell-like cells and nuclear inclusions/grooves resembling papillary thyroid carcinoma.

In primary pulmonary mucinous adenocarcinoma, ALK rearrangements were found in 34.2% and were significantly increased in the solid tumor with mucin production subtype, including signet ring cells, cribriform, and micropapillary patterns (PMID: 25813151).

Subcellular Level

  • Cytoplasm: Phase-separated EML4-ALK signaling foci (GO:0005737)
  • Plasma membrane: ALK receptor signaling (GO:0005886)
  • Microtubules: V3 re-localizes to microtubules upon inhibitor treatment (GO:0015630)
  • Nucleus: Downstream transcription factor activation (GO:0005634)

8. Temporal Development

Onset

  • Typical age of onset: Adult; median 55–60 years in most cohorts
  • Young-onset cases: 14.2% diagnosed before age 50 (median 44 years) (PMID: 31894386)
  • Onset pattern: Insidious; symptoms develop gradually over weeks to months

Disease Staging (AJCC 8th Edition)

Stage Description Treatment Approach
IB–IIIA Resectable early-stage Surgery + adjuvant alectinib (ALINA)
IIIB–IIIC Locally advanced Multimodal therapy
IV Metastatic First-line ALK TKI (lorlatinib/alectinib)

Progression

  • Natural history without treatment: Rapid progression, median OS ~12 months historically
  • With ALK TKI therapy: Dramatically prolonged course
  • Median PFS with lorlatinib: >5 years (not reached at 60 months) (PMID: 39231392)
  • Median OS with sequential TKIs: 81 months (6.8 years) (PMID: 30599201)
  • Progression pattern: Typically progressive; oligoprogression amenable to local therapy

Critical Periods

  • First-line TKI selection: Critical window determining long-term outcomes
  • Brain metastasis prevention: Early CNS-penetrant TKI (lorlatinib) prevents brain metastases in 96% of patients
  • Resistance emergence: Temporally restricted collateral sensitivities exist during adaptation, absent in therapy-naive or fully resistant cells

9. Inheritance and Population

Epidemiology

Prevalence of ALK rearrangement in NSCLC: - Overall: 3–7% of NSCLC - "The overall ALK gene rearrangement rate was 6.7% in 23,689 patients with advanced NSCLC and 8.2% in 17,436 patients with advanced lung adenocarcinoma" (PMID: 39016057) - "In a large cohort of 6576 non-small cell lung cancer patients, 343 (5.2%) cases harboring ALK rearrangements were identified" (PMID: 34271921)

Estimated incidence: Given ~2 million new lung cancer cases annually worldwide and ~85% being NSCLC, approximately 50,000–120,000 new ALK+ NSCLC cases occur per year globally.

Genetic Etiology

  • Inheritance pattern: Not inherited; exclusively somatic
  • Penetrance: Not applicable (somatic mutation)
  • Germline mosaicism: Not applicable

Population Demographics

Characteristic ALK+ NSCLC General NSCLC
Median age 55–60 years 65–70 years
Female proportion 50–58% 40–45%
Never-smoker 57–69% 10–15%
Adenocarcinoma >95% 40–50%
Asian ethnicity Enriched (43.9% in BC Canada cohort) Variable

Real-world data from multiple geographies confirm these demographics: - Argentina: Median age 55, 58% women, 57% nonsmokers (PMID: 41043103) - Canada: Median age 60, 68.9% never-smokers, 43.9% Asian (PMID: 40190818) - Taiwan: Median age 60, 49.9% female, 67.6% never-smokers (PMID: 39392550)

10. Diagnostics

Clinical Tests

Molecular Testing for ALK Rearrangement

Method Sensitivity Utilization Advantages
IHC (Ventana D5F3) 94–97% 53.6% (China) Rapid, inexpensive, reliable screen
FISH (break-apart) Gold standard 15.9% FDA-approved reference standard
RT-PCR High 25.4% Detects known fusion variants
NGS (DNA/RNA) 97%+ 18.3% Comprehensive; detects novel fusions

"IHC-VENTANA-D5F3 was used in 53.6%, real-time polymerase chain reaction (RT-PCR) in 25.4%, next-generation sequencing (NGS) in 18.3%, and fluorescence in-situ hybridization (FISH) in 15.9%" with intra-hospital consistency of 98.2% for IHC (PMID: 39016057).

Important: Discordant ALK IHC+/FISH- cases are "infrequent and associated with a worse outcome" on crizotinib, with PFS at 1 year 58% concordant vs 20% discordant (PMID: 31630043).

RNA-based NGS was confirmed as "the most efficient technique for gene fusion identification in clinical practice, allowing the simultaneous analysis of a large set of genomic rearrangements" (PMID: 37190044).

Imaging

  • CT chest: Standard for disease staging and response assessment
  • Brain MRI: Essential at diagnosis (29% brain metastases at presentation)
  • PET-CT: 18F-FDG PET for staging; shows rapid metabolic response to ALK TKIs
  • LDCT screening: Detects lung cancer at 0.5–1.2% rate in never-smokers; 78–89% early-stage (PMID: 41816408, PMID: 39465408)

Liquid Biopsy

  • ctDNA-based NGS: Useful for molecular profiling when tissue unavailable
  • CSF cfDNA: Superior to plasma for detecting CNS-specific alterations in brain metastases
  • Concordance: DNA-NGS concordance 97.1% for RNA-NGS, 94.7% for IHC, 97.4% for FISH (PMID: 35624360)

Histopathology

  • Biopsy findings: Adenocarcinoma with signet ring cells, cribriform/acinar patterns, extracellular mucin, psammoma bodies (PMID: 26095438)
  • IHC panel: ALK (D5F3), TTF-1, p40, PD-L1

Clinical Criteria

  • NCCN Guidelines recommend ALK testing for all non-squamous NSCLC and select squamous NSCLC
  • Testing should be performed at diagnosis before initiating first-line therapy
  • MAXO terms: molecular testing (MAXO:0000630), immunohistochemistry (MAXO:0000548), fluorescence in situ hybridization (MAXO:0000572)

Differential Diagnosis

  • ROS1-rearranged NSCLC (similar demographics, different fusion)
  • EGFR-mutant NSCLC (also in never-smokers but mutually exclusive with ALK)
  • RET-rearranged NSCLC
  • KRAS-mutant NSCLC (smoking-associated)
  • MET exon 14 skipping NSCLC

11. Outcome/Prognosis

Survival and Mortality

Stage IV disease (with ALK TKI therapy):

Metric Value Source
Median OS (sequential TKIs) 81 months (6.8 years) PMID: 30599201
Median OS (real-world) 54.0 months PMID: 36270866
5-year PFS (lorlatinib, 1L) 63% (Asian) PMID: 40024442
2-year DFS (adjuvant alectinib) 93.8% (stage II–IIIA) PMID: 38598794
2-year death rate 21% PMID: 36270866

"With a median follow-up time of 47 months, the median OS time from diagnosis of stage IV disease was 81 months (6.8 years)" (PMID: 30599201).

Prognostic Factors

Favorable: - EML4-ALK V1 (vs V3) - Wild-type TP53 - Single fusion isoform - Fewer metastatic organs at diagnosis - Treatment with next-generation ALK TKIs (vs crizotinib: HR=3.09 for progression/death) (PMID: 41043103)

Unfavorable: - EML4-ALK V3 (HR=1.53 for PFS vs V1) (PMID: 41959926) - TP53 co-mutation (V3+TP53: HR=9.1 for death) (PMID: 30255938) - Multiple fusion isoforms (HR=3.74 for OS) (PMID: 34626839) - Number of metastatic organs (HR=1.49 per additional organ) (PMID: 30599201) - Crizotinib monotherapy as only TKI

Brain Metastases

Brain metastases present at diagnosis in 29% of patients, with a cumulative incidence exceeding 50%. Lorlatinib provides dramatic CNS control: intracranial ORR 69% vs crizotinib 6% in patients with baseline brain metastases (PMID: 40024442). Complete and durable leptomeningeal regression has been documented with lorlatinib (PMID: 39008537).

12. Treatment

Pharmacotherapy: ALK Tyrosine Kinase Inhibitors

Generation Overview

Generation Drug Year Approved Key Targets Pivotal Trial
1st Crizotinib 2011 ALK/ROS1/MET PROFILE 1014
2nd Ceritinib 2014 ALK/IGF-1R/InsR ASCEND-4
2nd Alectinib 2015 ALK/RET ALEX, ALINA
2nd Brigatinib 2017 ALK/ROS1/IGF-1R/FLT3/EGFR ALTA-1L
2nd Ensartinib 2020 ALK/ROS1/MET eXalt3
3rd Lorlatinib 2018 ALK/ROS1 CROWN

KEGG Drug IDs: Crizotinib (D09731), Alectinib (D10450/D10542), Brigatinib (D10866), Ceritinib (D10551), Ensartinib (D11346/D11356), Lorlatinib (D11012)

Key Efficacy Data

Lorlatinib (CROWN trial, 5-year follow-up): - Median PFS: Not reached (>60 months) - 5-year PFS: 63% (Asian) vs 7% crizotinib (HR=0.22, 95%CI: 0.13–0.37) - Intracranial ORR: 69% vs 6% (brain metastases at baseline) - 96% probability of preventing brain metastases at 5 years (PMID: 40024442)

Alectinib (ALEX trial): - Median PFS: 34.8 months vs crizotinib 10.9 months (HR=0.43) (PMID: 30902613)

Adjuvant alectinib (ALINA trial): - "The percentage of patients alive and disease-free at 2 years was 93.8% in the alectinib group and 63.0% in the chemotherapy group among patients with stage II or IIIA disease (hazard ratio for disease recurrence or death, 0.24; 95% confidence interval [CI], 0.13 to 0.45; P<0.001)" (PMID: 38598794)

Cochrane meta-analysis of ALK TKIs vs chemotherapy (11 RCTs, 2874 patients): - ALK TKIs vs chemo: PFS HR=0.45 (95%CI: 0.40–0.52, high-certainty evidence) - Next-gen ALK TKIs vs crizotinib: PFS HR=0.39 (95%CI: 0.33–0.46, high-certainty evidence) - ORR in brain metastases: RR=4.88 vs chemo, RR=2.45 vs crizotinib (PMID: 34994987)

Safety Profiles

"The rates of grade 3–4 AEs were: alectinib (16.2%), crizotinib (46.4%), brigatinib (63.7%), ensartinib (75.6%), ceritinib (78.3%), and lorlatinib (91.6%)" (PMID: 37597303). No significant differences were found in fatal AEs or treatment discontinuation rates among the six TKIs.

Drug Key Toxicities
Crizotinib GI reactions, visual disorders, neutropenia, edema, hepatotoxicity
Alectinib Anemia, constipation (best tolerated overall)
Ceritinib Diarrhea, hepatotoxicity, elevated creatinine
Brigatinib GI reactions, hypertension, cough, headache
Ensartinib Skin disorders, pruritus, rash
Lorlatinib Hyperlipidemia (most frequent), neurocognitive effects (~20%), weight gain

"About 20% of patients receiving lorlatinib experienced cognitive effects and behavioral alterations in pivotal trials" (PMID: 35025076).

Renal effects: AKI occurred in 10% within 90 days of ALK TKI initiation; CKD developed in 14% within 1 year; most cases were mild and did not impact OS (PMID: 40382267).

Weight gain management: Lorlatinib-induced weight gain is manageable with structured exercise intervention including aerobic and resistance training (PMID: 41357598).

Pharmacogenomics

  • Crizotinib: CYP3A substrate with substantial interindividual PK variability; "patient survival is lower in the quartile with the lowest steady-state trough plasma concentrations" — pharmacoenhancement with cobicistat possible (PMID: 33222380)
  • Alectinib: CYP3A metabolized to active M4 metabolite; "potent CYP3A inhibition or induction resulted in only minor effects on the combined exposure of alectinib and M4" — favorable drug interaction profile (PMID: 27545757)
  • Lorlatinib: CYP3A substrate; strong CYP3A inducers significantly reduce exposure; avoid co-administration

Immunotherapy

ALK+ NSCLC shows limited benefit from immune checkpoint inhibitors due to the immune-cold phenotype. "First-line immunotherapy has limited activity in ALK-rearranged NSCLC; combination of immunotherapy and targeted agents raised safety concerns" (PMID: 30954906). Only 5–15% of metastatic NSCLC patients have EGFR/ALK driver mutations, and these are "largely excluded from immunotherapy trials" (PMID: 30642913). Rare complete responses to anti-PD1 + chemotherapy have been reported in patients with high PD-L1 expression (PMID: 39949598).

Surgical and Interventional

  • Surgical resection: Standard for early-stage (I–IIIA) disease with adjuvant alectinib
  • Stereotactic radiosurgery: For oligoprogressive brain metastases
  • Local ablative therapy: For oligoprogressive disease allowing continuation of systemic TKI (PMID: 31010758)

Experimental Therapies

  • ALK-directed ADC (CDX0239-PBD): Potent antitumor efficacy in ALK-expressing xenograft models; "ALK RNA, protein, and tumor cell surface expression is elevated in multiple pediatric and adult malignancies with minimal expression in childhood normal tissues" (PMID: 40813394)
  • Dual ALK + SRC inhibition: "Co-targeting of ALK and SRC showed remarkable inhibitory effects in both ALK-driven murine and ALK-patient-derived lung tumor cells" (PMID: 38521003)
  • YAP-targeting strategies: Cerivastatin (mevalonate pathway inhibitor) shows activity against ALK TKI resistance in vitro, in vivo, in patient-derived xenografts, and in EML4-ALK transgenic mice (PMID: 31633304)
  • HSP90 inhibitors: Cause rapid EML4-ALK degradation and transient tumor regression (PMID: 20952506)
  • ERBB3/AKT dual inhibition: Enhances apoptosis in EML4-ALK+ NSCLC cells (PMID: 39695132)
  • Clinical trials: NCT04318938 (ABP trial, brigatinib with deep phenotyping), NCT03052608 (CROWN), NCT03456076 (ALINA)

Treatment Strategy

Current recommended algorithm: 1. Molecular testing at diagnosis (IHC screen -> FISH/NGS confirmation) 2. Early-stage (resectable): Surgery + adjuvant alectinib x 24 months 3. Advanced/metastatic: First-line lorlatinib or alectinib 4. Progression: Rebiopsy for resistance mechanism -> targeted 2nd-line 5. Oligoprogression: Local ablative therapy + continue TKI

Sequential TKI treatment: Taiwan nationwide data demonstrated that treatment sequences including next-generation TKIs were independently associated with longer survival: G2 group median TTD 34.3 months vs G1 alone 7.5 months; G2 group OS HR=0.22 (95%CI: 0.15–0.31) vs crizotinib alone (PMID: 39392550).

MAXO terms: chemotherapy (MAXO:0000647), radiation therapy (MAXO:0000014), surgical resection (MAXO:0000448), targeted therapy (MAXO:0001525), molecular testing (MAXO:0000630)

13. Prevention

Primary Prevention

No specific primary prevention exists for ALK rearrangement as it is a stochastic somatic event. General lung cancer risk reduction includes: - Radon mitigation: Home radon testing and mitigation systems - Air pollution reduction: Environmental regulatory measures - Secondhand smoke avoidance: Smoke-free environments - Adequate cooking ventilation: Particularly in Asian populations

Secondary Prevention (Screening)

LDCT screening in never-smokers: - Thailand cohort: LC detection 1.2%, 69.8% stage 0–IB, 85% adenocarcinoma (PMID: 41816408) - China NCC: LC detection 1.0% in never-smokers vs 0.8% in smokers; 78.8% early-stage (PMID: 39465408) - South Korea: LC diagnosed in 0.47% of 17,968 never-smokers (PMID: 32482786)

"Current screening guidelines and eligibility criteria have limited efficacy in identifying LC cases (50%), as most screening programs primarily target subjects with a smoking history" (PMID: 38977146). Expanding LDCT to never-smokers with risk factors (family history, radon exposure) is an important unmet need.

The TALENT trial (Taiwan) specifically screens never-smokers aged 55–75 with risk factors including family history, passive smoke, TB history, and cooking exposure. Among 12,011 participants, lung cancer was diagnosed in 2.6%, with 77.4% at stage I. Family history of lung cancer and age >60 years were independently associated with increased risk (PMID: 38042167).

Tertiary Prevention

  • Adjuvant ALK TKI therapy: Prevents recurrence after surgery (ALINA trial: 2-year DFS 93.8% vs 63.0% for chemotherapy)
  • Brain metastasis prevention: CNS-penetrant TKIs (lorlatinib) prevent brain metastases in 96% of patients over 5 years
  • Resistance monitoring: Serial liquid biopsy for early detection of resistance mutations

14. Other Species / Natural Disease

ALK in Other Species

ALK is evolutionarily conserved and plays roles in nervous system development across species:

  • Drosophila melanogaster (NCBI Taxon: 7227): ALK ortholog (dAlk) regulates neuropeptide precursors; "The Alk receptor tyrosine kinase regulates Sparkly, a novel activity regulating neuropeptide precursor" (PMID: 38904987)
  • Mus musculus (NCBI Taxon: 10090): Mouse Alk gene (NCBI Gene: 11682); EML4-ALK transgenic models phenocopy human disease
  • Danio rerio (zebrafish): ALK ortholog expressed in developing nervous system

ALK in Other Cancer Types

ALK rearrangements/mutations drive multiple cancers across species: - Anaplastic large cell lymphoma (ALCL): NPM1-ALK fusion (KEGG: H01601) - Neuroblastoma: ALK point mutations and amplification (KEGG: H00043); NLRR1 acts as extracellular negative regulator of ALK signaling in neuroblastoma (PMID: 27604320) - Inflammatory myofibroblastic tumors (IMTs): Various ALK fusions, including novel rearrangements in neonates (PMID: 24290361) - Rhabdomyosarcoma: ALK overexpression (PMID: 40813394) - Peripheral T-cell lymphoma (KEGG: H01892)

Comparative Biology

ALK expression is "restricted to the developing nervous system" in normal tissues, with "minimal expression in childhood normal tissues" making it an attractive therapeutic target across species and cancer types (PMID: 40813394). The evolutionary conservation of ALK function from Drosophila to humans supports the use of cross-species models for studying ALK biology.

15. Model Organisms

Genetically Engineered Mouse Models

EML4-ALK transgenic mice: "We generated a genetically engineered mouse model that phenocopies the human disease where this rearranged gene arises" (PMID: 20952506). Key features: - Develops lung adenocarcinoma - Responsive to ALK TKIs (tumor regression with TAE684) - Shows greater tumor regression with ALK inhibitors than carboplatin/paclitaxel - HSP90 inhibitors cause rapid EML4-ALK degradation - Variant-specific models (V1, V3) established showing V3 confers worse ALK inhibitor response (PMID: 38521003)

Xenograft Models

Cell Line Characteristics Applications
NCI-H3122 EML4-ALK V1 (E13;A20) Drug testing, resistance studies
NCI-H2228 EML4-ALK V3 (E6;A20) Drug testing, intrapleural models
Patient-derived xenografts (PDX) Variable Personalized drug testing, resistance

"ASP3026 also showed potent antitumor activities, including tumor shrinkage to a nondetectable level, in hEML4-ALK transgenic mice and prolonged survival in mice with intrapleural NCI-H2228 xenografts" (PMID: 24419060).

YAP targeting was shown effective in both patient-derived xenografts and EML4-ALK transgenic mice for overcoming ALK TKI resistance (PMID: 31633304).

Patient-Derived Models

Patient-derived organoids (PDOs): Used for drug sensitivity testing in refractory ALK+ NSCLC. Case reports demonstrate clinical utility: "PDOs derived from primary and metastatic lesions may help optimize treatment regimens for patients with lung cancer brain metastases, thereby enabling personalized therapy" (PMID: 41114337).

In one case, a patient with complex EML4-ALK fusion variant 3 (E6:A20) and a novel NRXN1-ALK fusion who had progressed on multiple therapies showed PDO sensitivity to brigatinib, which subsequently induced a partial response sustained for 5.8 months.

Cell Line Models

  • NCI-H3122: Standard V1 model; used extensively for resistance studies including EGFR activation as bypass mechanism (PMID: 24199682)
  • NCI-H2228: V3 model; used for intrapleural and intrahepatic xenograft studies
  • EML4-ALK expressing normal human cells: EML4-ALK expression in mortal normal fibroblasts causes cellular senescence; hTERT co-expression enables transformation, providing isogenic model systems (PMID: 33761896)

Model Limitations

  • Mouse models do not fully recapitulate the immune microenvironment complexity
  • Xenograft models lack the tumor-stroma interactions of native disease
  • Species-specific differences in drug metabolism affect pharmacokinetic translation
  • Brain metastasis models are technically challenging to establish
  • PDO systems do not capture tumor-immune cell interactions

Key Findings: Detailed Evidence Summary

Finding 1: ALK Prevalence and Demographics

ALK rearrangements occur in 3–7% of NSCLC, predominantly in adenocarcinoma histology. The overall ALK gene rearrangement rate was 6.7% in 23,689 patients with advanced NSCLC (PMID: 39016057). The disease preferentially affects younger (median 55), female (50–58%), never-smoking (57–69%) patients (PMID: 22129856, PMID: 41043103, PMID: 40190818).

Finding 2: Variant-Specific Prognosis

EML4-ALK V3 confers worse prognosis than V1, with meta-analysis showing HR=1.53 (95%CI: 1.17–1.99, p=0.002) for PFS (PMID: 41959926). The combination of V3 + TP53 mutation is particularly lethal (HR=9.1 for death, p=0.02) (PMID: 30255938). The biophysical explanation involves differential phase separation properties and HSP90 dependence between variants (PMID: 37149843).

Finding 3: Dramatic TKI Efficacy

Lorlatinib achieved 5-year PFS of 63% in Asian patients (HR=0.22 vs crizotinib) with 96% brain metastasis prevention (PMID: 40024442). Adjuvant alectinib showed 2-year DFS of 93.8% vs 63.0% for chemotherapy (HR=0.24, P<0.001) (PMID: 38598794). Sequential TKI therapy yields median OS of 81 months (PMID: 30599201).

Finding 4: Multifaceted Resistance

Resistance evolves gradually through multiple cooperating mechanisms (PMID: 32409712) including secondary ALK mutations, bypass signaling (EGFR, SRC, AXL, ERBB3), EMT, YAP activation, and microenvironment adaptation via CAFs.

Finding 5: Immune-Cold Phenotype

Multi-omics studies consistently demonstrate ALK fusions are linked to immune-cold phenotypes with low TMB and poor T-cell infiltration (PMID: 41424613). The CD73/adenosine pathway, regulated by the ALK-ERK-Jun axis, contributes to immune evasion (PMID: 35598361).

Mechanistic Model: Integrated Pathophysiology

INITIATING EVENT
    Somatic inv(2)(p21p23) -> EML4-ALK fusion gene
|
MOLECULAR MECHANISM
    Constitutive ALK kinase activity
|
    +-----------+---------------+
    v           v               v
Phase-separated  HSP90 chaperone  Variant-specific
signaling foci   dependence       properties (V1 vs V3)
    |               |               |
    v               v               v
DOWNSTREAM SIGNALING
    +-- RAS-MAPK -> Proliferation + CD73 -> Immune evasion
    +-- PI3K-AKT-mTOR -> Survival + Growth
    +-- JAK-STAT3 -> Transcription + EMT potential
    +-- PLCgamma-ERK -> Proliferation
|
CELLULAR CONSEQUENCES
    +-- Uncontrolled proliferation
    +-- Anti-apoptotic signaling
    +-- Immune-cold microenvironment (low TMB, CD73/adenosine)
    +-- CNS tropism (brain metastases in >50%)
|
CLINICAL MANIFESTATION
    Lung adenocarcinoma -> Metastases (brain, bone, liver)
|
TREATMENT -> ALK TKI (dissolves signaling foci, blocks kinase)
|
RESISTANCE EVOLUTION (gradual, multifactorial)
    +-- ALK mutations (G1202R, L1196M, compound)
    +-- Bypass signaling (EGFR, SRC, AXL/GAS6, ERBB3)
    +-- Phenotypic: EMT (STAT3/Slug), YAP activation
    +-- Microenvironment: CAF-mediated resistance

Evidence Base: Key Literature

PMID Year Key Contribution
17625570 2007 Discovery of EML4-ALK fusion in NSCLC
20952506 2010 EML4-ALK transgenic mouse model; HSP90 dependence
22129856 2012 Demographic enrichment of ALK+ NSCLC
24199682 2014 EGFR activation as crizotinib resistance mechanism
26095438 2015 Histologic features of ALK+ adenocarcinoma
30255938 2018 V3+TP53 lethal subgroup identification
30599201 2019 6.8-year median OS natural history
30902613 2019 ALEX trial: alectinib 34.8-month PFS
31633304 2019 YAP as resistance mechanism and therapeutic target
32409712 2020 Gradual multifactorial resistance evolution
34661367 2021 Phase-separated EML4-ALK signaling foci
34626839 2021 Fusion isoform heterogeneity as prognostic factor
34994987 2021 Cochrane review of ALK TKIs (11 RCTs, 2874 patients)
35598361 2022 CD73/adenosine immune evasion mechanism
37149843 2023 Biophysical basis of V1 vs V3 drug sensitivity
37597303 2023 Network meta-analysis of ALK TKI safety
38598794 2024 ALINA trial: adjuvant alectinib
39016057 2024 Large-scale real-world ALK testing data
40024442 2025 CROWN 5-year data: lorlatinib PFS >60 months
41424613 2025 Multi-omics confirmation of immune-cold phenotype
41959926 2025 Meta-analysis: V3 vs V1 prognosis

Limitations and Knowledge Gaps

  1. No head-to-head trials comparing lorlatinib vs alectinib as first-line therapy; current comparisons rely on matching-adjusted indirect comparisons (MAIC)
  2. Optimal TKI sequencing remains undefined — which TKI should be used first, and what is the best sequence upon progression?
  3. Resistance to lorlatinib: Limited understanding of compound ALK mutations and strategies to overcome them
  4. Immunotherapy role: Optimal approaches to enhance immune response in the immune-cold ALK+ tumor microenvironment remain unclear; CD73/adenosine pathway inhibition is an untested clinical strategy
  5. Screening for never-smokers: No validated risk models for LDCT screening specifically targeting ALK+ NSCLC-prone populations
  6. Long-term outcomes: True 10-year survival data with modern TKI regimens are not yet mature
  7. Mechanisms of CNS tropism: Why ALK+ NSCLC shows preferential brain metastasis remains incompletely understood
  8. Epigenetic contributions: Role of DNA methylation and chromatin remodeling in ALK rearrangement susceptibility and resistance needs further study
  9. Germline susceptibility: Whether certain germline variants predispose to somatic ALK rearrangements is unknown
  10. Health disparities: Access to molecular testing and next-generation ALK TKIs varies dramatically globally

Proposed Follow-up Experiments/Actions

Clinical Priorities

  1. Head-to-head lorlatinib vs alectinib trial: Definitive comparison of the two leading first-line options, particularly for patients without brain metastases
  2. Fourth-generation ALK inhibitors: Development of agents active against compound mutations (G1202R + L1196M, etc.)
  3. CD73/adenosine pathway inhibitors + ALK TKI: Clinical trials combining ALK-targeted therapy with immune microenvironment modulation to overcome intrinsic immunotherapy resistance
  4. Circulating tumor DNA-guided adaptive therapy: Using serial ctDNA monitoring to detect resistance mutations early and guide therapy changes before radiographic progression
  5. LDCT screening trials for never-smokers: Expansion with risk models incorporating family history, radon exposure, and cooking fume exposure; integration with reflex molecular testing of detected nodules

Research Priorities

  1. Single-cell multi-omics of resistance: Characterizing the evolution of TKI resistance at single-cell resolution to identify therapeutic windows and collateral sensitivities
  2. ALK-directed ADCs: Clinical translation of antibody-drug conjugates (e.g., CDX0239-PBD) targeting ALK-expressing tumors
  3. Combination strategies for resistance: SRC+ALK inhibition, ERBB3+ALK inhibition, YAP/mevalonate pathway targeting
  4. Brain metastasis prevention biomarkers: Identifying patients at highest risk for CNS metastases who would benefit most from early CNS-penetrant therapy
  5. Patient-derived organoid platforms: Scaling PDO-guided therapy for personalized treatment selection in refractory disease, particularly for patients with complex or novel fusion variants

Ontology Term Summary

Disease Ontology

  • MONDO:0005233 (non-small cell lung carcinoma)
  • MONDO:0005061 (lung adenocarcinoma)
  • NCIT:C215346 (ALK-Positive Lung Non-Small Cell Carcinoma)

Phenotype Ontology (HPO)

  • HP:0100526 (Neoplasm of the lung)
  • HP:0012735 (Cough)
  • HP:0002094 (Dyspnea)
  • HP:0002105 (Hemoptysis)
  • HP:0001824 (Weight loss)
  • HP:0100749 (Chest pain)
  • HP:0002202 (Pleural effusion)
  • HP:0100634 (Brain metastases)
  • HP:0012378 (Fatigue)

Gene Ontology (Biological Process)

  • GO:0006468 (protein phosphorylation)
  • GO:0000165 (MAPK cascade)
  • GO:0008283 (cell proliferation)
  • GO:0007165 (signal transduction)
  • GO:0006915 (apoptotic process)
  • GO:0016477 (cell migration)
  • GO:0001837 (epithelial to mesenchymal transition)

Gene Ontology (Cellular Component)

  • GO:0005737 (cytoplasm)
  • GO:0005886 (plasma membrane)
  • GO:0015630 (microtubule cytoskeleton)
  • GO:0005634 (nucleus)

Cell Ontology (CL)

  • CL:0002063 (type II pneumocyte)
  • CL:0000082 (epithelial cell of lung)
  • CL:0002328 (bronchial epithelial cell)

Anatomy Ontology (UBERON)

  • UBERON:0002048 (lung)
  • UBERON:0002185 (bronchus)
  • UBERON:0000955 (brain)
  • UBERON:0000977 (pleura)
  • UBERON:0002107 (liver)
  • UBERON:0002481 (bone tissue)
  • UBERON:0002369 (adrenal gland)

Chemical Entities (CHEBI)

  • Crizotinib (KEGG: D09731)
  • Alectinib (KEGG: D10450)
  • Lorlatinib (KEGG: D11012)
  • Brigatinib (KEGG: D10866)
  • Ceritinib (KEGG: D10551)
  • Ensartinib (KEGG: D11346)

Medical Action Ontology (MAXO)

  • MAXO:0000647 (chemotherapy)
  • MAXO:0000014 (radiation therapy)
  • MAXO:0000448 (surgical resection)
  • MAXO:0001525 (targeted therapy)
  • MAXO:0000630 (molecular testing)
  • MAXO:0000548 (immunohistochemistry)
  • MAXO:0000572 (fluorescence in situ hybridization)

Report generated from systematic analysis of 129 papers, 22 confirmed findings, across 5 investigation iterations. All citations verified against original abstracts. Last updated: 2026-05-06.